[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 492
1. Lambert B, Bacher K, De Keukeleire K, Smeets P, Colle I, Jeong JM, Thierens H, Troisi R, De Vos F, Van de Wiele C: 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis. J Nucl Med; 2005 Aug;46(8):1326-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis.
  • This study aimed to investigate the feasibility of the intraarterial administration of 3.7 GBq (188)Re-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/lipiodol ((188)Re-HDD/lipiodol) for treatment of hepatocellular carcinoma (HCC) in patients with moderately advanced cirrhosis.
  • [MeSH-major] Carcinoma, Hepatocellular / complications. Carcinoma, Hepatocellular / radiotherapy. Iodized Oil / adverse effects. Iodized Oil / therapeutic use. Liver Cirrhosis / etiology. Liver Cirrhosis / prevention & control. Organometallic Compounds / adverse effects. Organometallic Compounds / therapeutic use. Radiation Injuries / etiology
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Humans. Middle Aged. Pilot Projects. Radiopharmaceuticals / adverse effects. Radiopharmaceuticals / therapeutic use. Severity of Illness Index. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085590.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 188Re-4-hexadecyl-1,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol lipiodol conjugate; 0 / Organometallic Compounds; 0 / Radiopharmaceuticals; 8001-40-9 / Iodized Oil
  •  go-up   go-down


2. Ito K, Arai M, Imazeki F, Yonemitsu Y, Bekku D, Kanda T, Fujiwara K, Fukai K, Sato K, Itoga S, Nomura F, Yokosuka O: Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol; 2010;45(2):243-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
  • OBJECTIVE: To determine the risk factors for the occurrence of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) infection.
  • CONCLUSIONS: Advanced age and low PLT level were risk factors for HCC occurrence in patients with HBV infection.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Hepatitis B, Chronic / complications. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Alanine Transaminase / metabolism. DNA, Viral / genetics. Female. Hepatitis B e Antigens / metabolism. Hepatitis B virus / genetics. Humans. Male. Middle Aged. Platelet Count. Retrospective Studies. Risk Assessment / methods. Risk Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20095888.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B e Antigens; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


3. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N: Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol; 2005 Dec;43(6):1013-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.
  • BACKGROUND/AIMS: MHC class I-related chain A (MICA), a human ligand of natural killer (NK) cell stimulatory receptor NKG2D, is expressed in human hepatocellular carcinomas (HCC).
  • RESULTS: The levels of sMICA were frequently elevated in patients with advanced HCC.
  • In vitro experiments revealed that sMICA derived from advanced HCC was responsible for down-modulation of NKG2D expression and NK cell functions.
  • NK cells upon stimulation of human hepatoma cells induced maturation of DC and enhanced the allostimulatory capacity of DC; maturation and activation of DC were completely abolished when NK cells were pre-treated with sMICA-containing serum.
  • CONCLUSIONS: sMICA is present in sera of patients with advanced HCC and may serve as a tumor evasion mechanism by negatively modulating both innate and adaptive immunity.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Dendritic Cells / immunology. Histocompatibility Antigens Class I / immunology. Killer Cells, Natural / immunology. Liver Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis, Chronic / immunology. Humans. Male. Middle Aged. NK Cell Lectin-Like Receptor Subfamily K. Receptors, Immunologic / immunology. Receptors, Natural Killer Cell

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168521.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / KLRK1 protein, human; 0 / MHC class I-related chain A; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Receptors, Immunologic; 0 / Receptors, Natural Killer Cell
  •  go-up   go-down


Advertisement
4. Yuen MF, Hou JL, Chutaputti A, Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma: Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol; 2009 Mar;24(3):346-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in the Asia pacific region.
  • Primary liver cancer, particularly hepatocellular carcinoma (HCC) remains a significant disease worldwide.
  • The majority of patients present with advanced diseases, hence reducing the chance of curative treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Liver Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Asia / epidemiology. Asian Continental Ancestry Group. Female. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / epidemiology. Humans. Incidence. Male. Middle Aged. Odds Ratio. Prevalence. Prognosis. Risk Assessment. Risk Factors. Sex Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220670.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Number-of-references] 35
  • [Investigator] Farrell GC; Chan HL; Yuen MF; Amarapurkar DN; Chutaputti A; Fan JG; Hou JL; Han KH; Kao JH; Lim SG; Mohamed R; Sollano J; Ueno Y
  •  go-up   go-down


5. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS, HALT-C Trial Group: Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology; 2010 Sep;52(3):833-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
  • Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis who achieve a sustained virological response (SVR) have a lower risk of hepatic decompensation and hepatocellular carcinoma (HCC).
  • CONCLUSION: Patients with advanced chronic hepatitis C who achieved SVR had a marked reduction in death/liver transplantation, and in liver-related morbidity/mortality, although they remain at risk for HCC.
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / epidemiology. Cohort Studies. Female. Follow-Up Studies. Humans. Liver / pathology. Liver Neoplasms / epidemiology. Male. Middle Aged. Prognosis. Prospective Studies. Recombinant Proteins. Recurrence. Risk Factors. Severity of Illness Index. Survival Rate. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2002 May;122(5):1303-13 [11984517.001]
  • [Cites] Gastroenterology. 2009 Dec;137(6):1986-94 [19747918.001]
  • [Cites] Hepatology. 2004 Feb;39(2):333-42 [14767986.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1616-22 [15378504.001]
  • [Cites] Control Clin Trials. 2004 Oct;25(5):472-92 [15465617.001]
  • [Cites] Hepatology. 1998 May;27(5):1394-402 [9581697.001]
  • [Cites] Hepatology. 1999 Apr;29(4):1124-30 [10094956.001]
  • [Cites] Ann Intern Med. 2005 Jan 18;142(2):105-14 [15657158.001]
  • [Cites] Hepatology. 2005 Aug;42(2):282-92 [15986415.001]
  • [Cites] Hepatology. 2007 Mar;45(3):579-87 [17326216.001]
  • [Cites] J Viral Hepat. 2007 Aug;14(8):556-63 [17650289.001]
  • [Cites] Ann Intern Med. 2007 Nov 20;147(10):677-84 [18025443.001]
  • [Cites] N Engl J Med. 2008 Dec 4;359(23):2429-41 [19052125.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):138-48 [18848939.001]
  • [Cites] Hepatology. 2009 Mar;49(3):729-38 [19072828.001]
  • [Cites] Hepatology. 2003 Aug;38(2):493-502 [12883494.001]
  • (PMID = 20564351.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00006164
  • [Grant] United States / NIDDK NIH HHS / DK / N01-DK-9-2325; United States / NCRR NIH HHS / RR / M01RR-00042; United States / NCRR NIH HHS / RR / 1 UL1 RR 025780-01; United States / NCRR NIH HHS / RR / M01RR-00065; United States / NIDDK NIH HHS / DK / N01-DK-9-2328; United States / NIDDK NIH HHS / DK / N01-DK-9-2318; United States / NIDDK NIH HHS / DK / N01-DK-9-2324; United States / NIDDK NIH HHS / DK / N01-DK-9-2319; United States / NCRR NIH HHS / RR / M01RR-00051; United States / NCRR NIH HHS / RR / UL1 RR025780; United States / NCRR NIH HHS / RR / 1 UL1 RR024986; United States / NCRR NIH HHS / RR / 1 UL1 RR025758-01; United States / NIDDK NIH HHS / DK / N01-DK-9-2321; United States / NCRR NIH HHS / RR / M01RR-00827; United States / NIDDK NIH HHS / DK / N01-DK-9-2327; United States / NCRR NIH HHS / RR / M01RR-01066; United States / NCRR NIH HHS / RR / 1 UL1 RR024982-01; United States / NIDDK NIH HHS / DK / N01-DK-9-2320; United States / NCRR NIH HHS / RR / M01 RR000827-346336; United States / NCRR NIH HHS / RR / M01 RR006192; United States / NIDDK NIH HHS / DK / N01 DK092323; United States / NCRR NIH HHS / RR / M01 RR001066; United States / NCRR NIH HHS / RR / M01 RR000827-337091; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCRR NIH HHS / RR / M01 RR000065; United States / NCRR NIH HHS / RR / UL1 RR024982; United States / NCRR NIH HHS / RR / M01 RR000051; United States / NIDDK NIH HHS / DK / N01-DK-9-2326; United States / NIDDK NIH HHS / DK / N01-DK-9-2322; United States / NCRR NIH HHS / RR / M01 RR000043; United States / NIDDK NIH HHS / DK / N01-DK-9-2323; United States / NCRR NIH HHS / RR / UL1 RR025758; United States / NCRR NIH HHS / RR / M01 RR000042; United States / NCRR NIH HHS / RR / M01 RR000827; United States / NCRR NIH HHS / RR / M01RR-00633; United States / NCRR NIH HHS / RR / M01RR-00043; United States / NCRR NIH HHS / RR / M01RR-06192; United States / NCRR NIH HHS / RR / UL1 RR024986
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 30IQX730WE / Polyethylene Glycols; 47RRR83SK7 / interferon alfa-2a; 49717AWG6K / Ribavirin; Q46947FE7K / peginterferon alfa-2a
  • [Other-IDs] NLM/ NIHMS207625; NLM/ PMC2932862
  •  go-up   go-down


6. Uematsu S, Higashi T, Nouso K, Kariyama K, Nakamura S, Suzuki M, Nakatsukasa H, Kobayashi Y, Hanafusa T, Tsuji T, Shiratori Y: Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol; 2005 Apr;20(4):583-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.
  • BACKGROUND: Advanced hepatocellular carcinoma (HCC) in humans is characterized by hypervascularity.
  • [MeSH-major] Carcinoma, Hepatocellular / blood. Endostatins / blood. Fibroblast Growth Factor 2 / blood. Liver Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoenzyme Techniques. Liver Cirrhosis. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15836707.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Endostatins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


7. Ohwada S, Hamada K, Kawate S, Sunose Y, Tomizawa N, Yamada T, Okabe T, Ogawa T, Sato Y: Left renal vein graft for vascular reconstruction in abdominal malignancy. World J Surg; 2007 Jun;31(6):1215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Advanced abdominal malignancies are occasionally invasive for the major blood vessels, such as the portal vein (PV), inferior vena cava (IVC), and major hepatic veins (HVs), and complete removal of the tumors is required for patients undergoing vascular resection and reconstruction.
  • The PV and SMV were resected in 5 patients undergoing pancreaticoduodenectomy for pancreatic carcinoma, and in 1 patient being treated with extended right hepatectomy and pancreaticoduodenectomy for hepatic hilar carcinoma.
  • The IVC was partially resected in 1 patient with advanced colon cancer and 1 with malignant schwannoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / pathology. Bile Ducts, Intrahepatic / surgery. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Female. Follow-Up Studies. Hepatectomy. Hospital Mortality. Humans. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Liver Neoplasms / mortality. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Microsurgery. Middle Aged. Neoplasm Invasiveness. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy. Postoperative Complications / mortality. Tomography, X-Ray Computed. Vascular Patency / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Transpl. 2006 Aug;12(8):1233-6 [16724339.001]
  • [Cites] J Am Coll Surg. 1995 Apr;180(4):497-8 [7719560.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):241-7 [12170030.001]
  • [Cites] J Gastrointest Surg. 2005 Mar;9(3):353-6 [15749595.001]
  • [Cites] J Am Coll Surg. 2006 Jan;202(1):87-92 [16377501.001]
  • [Cites] World J Surg. 2000 Mar;24(3):377-82 [10658076.001]
  • [Cites] Langenbecks Arch Surg. 2004 Apr;389(2):110-3 [15004752.001]
  • [Cites] Am J Transplant. 2005 Jun;5(6):1339-46 [15888039.001]
  • [Cites] Surg Today. 1995;25(4):378-80 [7633133.001]
  • [Cites] Hepatogastroenterology. 1998 Sep-Oct;45(23):1833-6 [9840158.001]
  • [Cites] Hepatogastroenterology. 1997 Nov-Dec;44(18):1619-23 [9427033.001]
  • [Cites] Hepatogastroenterology. 2006 Jul-Aug;53(70):479-83 [16995445.001]
  • [Cites] Arch Surg. 1990 Nov;125(11):1455-9 [2241557.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):850-8 [12035042.001]
  • [Cites] J Am Coll Surg. 1999 Jan;188(1):63-71 [9915245.001]
  • [Cites] Surgery. 1990 Nov;108(5):913-8 [2237772.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1151-5 [10370683.001]
  • [Cites] J Surg Oncol. 2006 Mar 15;93(4):338-42 [16496372.001]
  • [Cites] J Nephrol. 2002 Mar-Apr;15(2):186-90 [12018637.001]
  • [Cites] AJR Am J Roentgenol. 1982 Oct;139(4):703-9 [6981932.001]
  • [Cites] Radiology. 1995 Nov;197(2):351-6 [7480676.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1581-5 [15532782.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1823-6 [10430353.001]
  • [Cites] Surgery. 1993 Jul;114(1):59-64 [8356528.001]
  • (PMID = 17453283.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Kim SJ, Seo HY, Choi JG, Sul HR, Sung HJ, Park KH, Choi IK, Oh SC, Yoon SY, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS: Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol; 2006 Apr;57(4):436-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
  • PURPOSE: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide.
  • Because HCC usually presents as an advanced disease and occurs in the background of liver cirrhosis, most patients are not suitable for treatment with curative intent, thus effective systemic chemotherapy is required.
  • However, the outcome of systemic chemotherapy has been disappointing in advanced HCC.
  • This study was conducted to test the efficacy and toxicity of the combined regimen of epirubicin, cisplatin, and UFT moderated by leucovorin in advanced or recurrent HCC.
  • However, a randomized phase III trial based on this regimen is warranted to clarify its survival benefit in patients with advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antidotes / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Epirubicin / administration & dosage. Female. Hematologic Diseases / blood. Hematologic Diseases / chemically induced. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Survival Analysis. Tegafur / administration & dosage. Tomography, X-Ray Computed. Treatment Outcome. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049620.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antidotes; 0 / Antineoplastic Agents; 1548R74NSZ / Tegafur; 3Z8479ZZ5X / Epirubicin; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; 1-UFT protocol
  •  go-up   go-down


9. Raja NS, Janjua KA: Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect; 2008 Feb;41(1):4-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although at present a small proportion of those with chronic HCV infection develop liver failure or hepatocellular carcinoma, it is estimated that the incidence of these advanced disease complications will increase over the coming years.
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / etiology. Female. Genotype. Humans. Male. Middle Aged. Pakistan / epidemiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18327420.001).
  • [ISSN] 1684-1182
  • [Journal-full-title] Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
  • [ISO-abbreviation] J Microbiol Immunol Infect
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 39
  •  go-up   go-down


10. Seo YS, Kim JN, Keum B, Park S, Kwon YD, Kim YS, Jeen YT, Chun HJ, Kim CY, Kim CD, Ryu HS, Um SH: Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma. World J Gastroenterol; 2008 Apr 21;14(15):2394-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma.
  • AIM: To evaluate the efficacy of radiotherapy (RT) in patients with advanced unresectable hepatocellular carcinoma (HCC).
  • CONCLUSION: RT is effective in treating advanced HCC with a tumor response rate of 56.9%.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy / adverse effects. Risk Assessment. Severity of Illness Index. Time Factors. Treatment Outcome. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):435-42 [10802371.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1331-5 [10889387.001]
  • [Cites] Strahlenther Onkol. 2000 Sep;176(9):406-10 [11050913.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):150-5 [12182985.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):329-36 [12527045.001]
  • [Cites] World J Gastroenterol. 2003 Sep;9(9):1885-91 [12970869.001]
  • [Cites] Clin Oncol. 1979 Mar;5(1):25-31 [217565.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Jan;12(1):31-5 [3080390.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1194-203 [2441837.001]
  • [Cites] Arch Surg. 1989 Sep;124(9):1025-8 [2549912.001]
  • [Cites] Surgery. 1989 Oct;106(4):740-8; discussion 748-9 [2799650.001]
  • [Cites] Surgery. 1990 May;107(5):511-20 [2159190.001]
  • [Cites] Cancer. 1991 Nov 15;68(10):2150-4 [1655202.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):920-4 [1370918.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):62-5 [8380123.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1286-93 [8391066.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1204-11 [8201383.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1237-48 [7713785.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):42-6 [7740809.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1077-85 [9392547.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):393-7 [10030267.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Oct;14(10):941-5 [10530488.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1965 Jan;93:200-8 [14243011.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1143-50 [15752895.001]
  • [Cites] World J Gastroenterol. 2005 Mar 21;11(11):1697-9 [15786553.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2210-8 [10829040.001]
  • (PMID = 18416468.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC2705096
  •  go-up   go-down


11. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M: Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis; 2010 May;42(5):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal.
  • Although not frequently, hepatocellular carcinoma (HCC) can ensue in a non-cirrhotic liver.
  • (c) a more advanced tumour stage at the time of diagnosis, as it is usually detected due to the occurrence of cancer-related symptoms, outside any scheduled surveillance program;.
  • (e) overall and disease-free survivals after resection of non-advanced tumours (meeting the Milano criteria) comparable to that obtained with liver transplantation in cirrhotic patients carrying an early tumour;.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepatitis, Viral, Human / complications. Liver Neoplasms / virology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Alcoholism / complications. Disease-Free Survival. Female. Hepatectomy. Humans. Male. Middle Aged. Prejudice. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19828388.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 105
  •  go-up   go-down


12. Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L: A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs; 2008 Jun;26(3):265-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
  • Hepatocellular carcinoma (HCC) remains a lethal treatment-resistant cancer with a median survival of <6 months in patients not considered candidates for radical surgical treatments.
  • Based on evidence from preclinical models and phase I trials, we conducted a phase II trial of SB-715992 in chemo-naïve patients with advanced HCC.
  • A non-randomized, non-blinded multicentre two-stage phase II study was completed examining the efficacy, toxicity, and pharmacokinetics of SB-715992 at 18 mg/m2 IV q 3 weeks, in patients with measurable locally advanced, metastatic or recurrent HCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzamides / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Expression. Humans. Infusions, Intravenous. Kinesin / antagonists & inhibitors. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):127-34 [12735134.001]
  • [Cites] Radiology. 2002 Jul;224(1):47-54 [12091661.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Hepatology. 2000 Sep;32(3):679-80 [10991637.001]
  • [Cites] Curr Opin Pharmacol. 2001 Aug;1(4):370-7 [11710735.001]
  • [Cites] Cell Growth Differ. 1992 Aug;3(8):531-40 [1356418.001]
  • [Cites] Science. 2000 Apr 7;288(5463):88-95 [10753125.001]
  • [Cites] Semin Liver Dis. 1999;19(3):311-22 [10518310.001]
  • [Cites] Cancer Lett. 1999 Jan 8;135(1):97-105 [10077227.001]
  • [Cites] Expert Opin Pharmacother. 2003 Dec;4(12):2175-85 [14640916.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):479-83 [2839280.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1094-101 [10694562.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • (PMID = 18196204.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / KIF11 protein, human; 0 / Quinazolines; BKT5F9C2NI / ispinesib; EC 3.6.4.4 / Kinesin
  •  go-up   go-down


13. Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, Lau WY, Wu MC, Cheng SQ: A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol; 2010 Jan;17(1):179-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection.
  • BACKGROUND: The role of antiviral therapy for patients in the immune-active phase of hepatitis B virus (HBV) infection who underwent partial hepatectomy for hepatocellular carcinoma (HCC) is unknown.
  • METHODS: From January 2004 to June 2007, a nonrandomized comparative study for postoperative antiviral treatment was conducted on patients who underwent curative hepatectomy for advanced HCC.
  • [MeSH-major] Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatitis B / drug therapy. Hepatitis B virus / immunology. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Hepatitis B Surface Antigens / metabolism. Hepatitis B e Antigens / immunology. Humans. Liver Function Tests. Male. Middle Aged. Postoperative Period. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727956.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B e Antigens
  •  go-up   go-down


14. Huang JH, Fan WJ, Li CJ, Gu YK, Zhang L, Gao F, Lu LW, Li WQ: Application of multislice spiral CT angiography on transcatheter arterial chemoembolization for hepatocellular carcinoma. Ai Zheng; 2009 Feb;28(2):159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of multislice spiral CT angiography on transcatheter arterial chemoembolization for hepatocellular carcinoma.
  • This study was to investigate the clinical application of MSCTA on transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) by comparing images of MSCTA and digital subtraction angiography (DSA).
  • METHODS: MSCT dual-phase enhanced scanning was performed in 50 patients with advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / radiography. Chemoembolization, Therapeutic / methods. Liver Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Angiography / methods. Angiography, Digital Subtraction / methods. Arteriovenous Fistula / radiography. Female. Hepatic Artery / radiography. Humans. Imaging, Three-Dimensional / methods. Male. Middle Aged. Portal Vein / radiography. Reproducibility of Results. Venous Thrombosis / radiography. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550129.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D'Onofrio M, Guglielmi A: Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. J Gastrointest Surg; 2009 Jul;13(7):1313-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients.
  • BACKGROUND AND OBJECTIVE: The role of liver resection in advanced hepatocellular carcinoma (multinodular or with macroscopic vascular involvement) is still controversial.
  • The aim of this study is to evaluate the role of surgical resection compared to other therapeutic modalities in patients with advanced hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Needle. Cohort Studies. Diagnostic Imaging / methods. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Liver Function Tests. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Registries. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplant Proc. 2005 May;37(4):1693-4 [15919433.001]
  • [Cites] Gastroenterology. 2008 Jun;134(7):1908-16 [18549877.001]
  • [Cites] World J Gastroenterol. 2001 Feb;7(1):28-32 [11819728.001]
  • [Cites] Hepatology. 1999 Jan;29(1):62-7 [9862851.001]
  • [Cites] HPB (Oxford). 2003;5(4):206-13 [18332989.001]
  • [Cites] Semin Liver Dis. 2005;25(2):181-200 [15918147.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2008 Jun;7(3):237-57 [18522878.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):940-6 [16788755.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):35-50, viii [12735128.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):480-4 [12749252.001]
  • [Cites] Ann Surg Oncol. 2008 Apr;15(4):979-85 [18236115.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Liver Transpl. 2005 Sep;11(9):1086-92 [16123959.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):100-4 [12511161.001]
  • [Cites] World J Gastroenterol. 2005 Feb 28;11(8):1215-9 [15754408.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):364-73 [15915370.001]
  • [Cites] Hepatol Res. 2007 Sep;37(9):676-91 [17617112.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] J Surg Oncol. 2003 Feb;82(2):98-103 [12561065.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):386-91 [9708639.001]
  • [Cites] Ann Surg. 1990 Mar;211(3):277-87 [2155591.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Nov;2(4):513-9 [14627511.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):379-84 [11224626.001]
  • (PMID = 19418103.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Huang YH, Chen CH, Chang TT, Chen SC, Wang SY, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, Lee PC, Chau GY, Lui WY, Lee SD, Wu JC: Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. J Gastroenterol Hepatol; 2005 May;20(5):765-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery.
  • BACKGROUND: An accurate staging system is required to assess hepatocellular carcinoma (HCC) patients in order to benefit from hepatic resection before surgery.
  • Whether JIS score is feasible for those patients with advanced HCC needs further evaluation.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / mortality. Liver Neoplasms / pathology. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Hepatectomy. Humans. Male. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853992.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


17. Kornberg A, Freesmeyer M, Bärthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D, Settmacher U: 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant; 2009 Mar;9(3):592-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients.
  • Vascular invasion of hepatocellular carcinoma (HCC) is a major risk factor for poor outcome after liver transplantation (LT).
  • Patients with advanced PET negative tumors and patients with HCC meeting the Milan criteria had a comparable 3-year-recurrence-free survival (80% vs. 94%, p = 0.6).
  • [MeSH-major] Carcinoma, Hepatocellular / blood supply. Carcinoma, Hepatocellular / pathology. Fluorodeoxyglucose F18. Liver Neoplasms / blood supply. Liver Neoplasms / pathology. Liver Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Positron-Emission Tomography. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Transplant. 2009 May;9(5):1255.. Settmacher, U [added]
  • (PMID = 19191771.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Yu JC, Neugut AI, Wang S, Jacobson JS, Ferrante L, Khungar V, Lim E, Hershman DL, Brown RS Jr, Siegel AB: Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer; 2010 Apr 1;116(7):1801-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma.
  • BACKGROUND: : Patients with hepatocellular carcinoma (HCC) have a poor prognosis if their tumors are not diagnosed early.
  • Black and Hispanic patients, and Medicaid recipients, presented with more advanced disease than whites and privately insured patients, and had poorer survival.
  • CONCLUSIONS: : Race and insurance status were strongly associated with receipt of transplantation and with more advanced disease at diagnosis, but transplantation was the most important determinant of survival.

  • MedlinePlus Health Information. consumer health - Health Disparities.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1661-9 [10572155.001]
  • [Cites] Dig Dis Sci. 2009 Sep;54(9):2031-9 [19117131.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] Am J Kidney Dis. 2004 Feb;43(2):350-7 [14750101.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2):235-43 [14762861.001]
  • [Cites] Arch Surg. 2004 Sep;139(9):992-6 [15381619.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Hepatology. 1997 Jun;25(6):1485-9 [9185772.001]
  • [Cites] Liver Transpl Surg. 1998 Nov;4(6):499-505 [9791161.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1198-205 [10519898.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):510-7 [15659496.001]
  • [Cites] J Hepatol. 2006 Jan;44(1):158-66 [16290309.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jan;4(1):104-10; quiz 4-5 [16431312.001]
  • [Cites] Clin Transplant. 2006 Nov-Dec;20(6):769-75 [17100728.001]
  • [Cites] Hepatology. 2007 May;45(5):1282-9 [17464970.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1636-46; discussion 1646 [17912593.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):120-7 [18005365.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):551-5 [17562173.001]
  • [Cites] Am J Gastroenterol. 2008 Apr;103(4):901-10 [18371131.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1342-51 [18471511.001]
  • [Cites] JAMA. 2008 Nov 26;300(20):2371-8 [19033587.001]
  • [Cites] Dig Dis Sci. 2009 Aug;54(8):1794-7 [19051029.001]
  • [Cites] J Gen Intern Med. 2001 Dec;16(12):815-21 [11903760.001]
  • (PMID = 20143441.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR024157-03; United States / NCRR NIH HHS / RR / K12 RR024157-03; United States / NCI NIH HHS / CA / K23 CA149084; United States / NCRR NIH HHS / RR / KL2 RR024157; United States / NIA NIH HHS / AG / P30 AG135294-10; United States / NCRR NIH HHS / RR / KL2 RR024157-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS394250; NLM/ PMC3664455
  •  go-up   go-down


19. Gotohda N, Ishii H, Konishi M, Nakagohri T, Takahashi S, Furuse J, Yoshino M, Kinoshita T: Selection criteria for reduction hepatectomy in multiple advanced hepatocellular carcinoma. Anticancer Res; 2006 Nov-Dec;26(6C):4671-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selection criteria for reduction hepatectomy in multiple advanced hepatocellular carcinoma.
  • BACKGROUND: Few studies have compared the prognostic impact of reduction hepatectomy (RH) for advanced hepatocellular carcinoma (HCC) with that of non-surgical treatment or curative hepatectomy.
  • CONCLUSION: RH could be recommended to patients with multiple advanced HCC extending to >50% of the whole liver.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatectomy. Humans. Male. Middle Aged. Patient Selection. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214325.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


20. Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, Hatanaka K, Kitai S, Ishikawa E, Inoue T, Hagiwara S, Minami Y, Chung H: Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology; 2008;75 Suppl 1:106-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.
  • PURPOSE: There are currently no effective treatments for patients with advanced hepatocellular carcinoma (HCC) with vascular invasion or extrahepatic metastases.
  • We evaluated the efficacy and safety of combination therapy with S-1 and pegylated interferon (PEG-IFN)-alpha for advanced HCC.
  • CONCLUSION: Combination therapy with S-1 and PEG-IFN is effective and feasible, and is therefore a promising regimen for advanced HCC.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Interferon-alpha / administration & dosage. Liver Neoplasms / drug therapy. Oxonic Acid / administration & dosage. Polyethylene Glycols / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Combinations. Drug Therapy, Combination. Feasibility Studies. Female. Humans. Male. Middle Aged. Recombinant Proteins. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 19092279.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 0 / peginterferon alfa-2b; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 30IQX730WE / Polyethylene Glycols; 5VT6420TIG / Oxonic Acid; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


21. Lang H, Sotiropoulos GC, Brokalaki EI, Radtke A, Frilling A, Molmenti EP, Malagó M, Broelsch CE: Left hepatic trisectionectomy for hepatobiliary malignancies. J Am Coll Surg; 2006 Sep;203(3):311-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival corresponding to the four most frequent tumor types (hepatocellular carcinoma, cholangiocellular carcinoma, hilar cholangiocarcinoma, and colorectal metastases) was comparable with survival data reported in the literature after less-extensive resections.
  • CONCLUSIONS: Left trisectionectomy provides acceptable survival rates in both locally advanced primary hepatobiliary malignancies and large metastatic liver tumors.
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Colorectal Neoplasms / secondary. Female. Gallbladder Neoplasms / pathology. Gallbladder Neoplasms / surgery. Humans. Male. Middle Aged. Postoperative Complications. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931303.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Maria S, Gaetano LG, Rosanna PT, Rosario L, Elisa M, Antonietta TM, Domenico R, Stefano P: Analysis of BCLC treatment indications. Have BCLC modified our choice of treatment in HCC patients? A retrospective study. Hepatogastroenterology; 2009 Jul-Aug;56(93):1090-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: The Barcelona Clinic Liver Cancer (BCLC) classification has been recently validated as the best system for treatment guidance for hepatocellular carcinoma (HCC), but it doesn't properly consider liver dysfunction.
  • About the undertreatment cases we didn't perform hepatic resection such as BCLC suggests because of advanced age and/or high level of IGC; in patients in whom BCLC would suggest chemoembolization, we supposed this treatment as high risk therapy.
  • [MeSH-major] Algorithms. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis. Tumor Burden

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760948.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


23. Lin JC, Shih YL, Chien PJ, Liu CL, Lee JJ, Liu TP, Ko WC, Shih CM: Increased percentage of B cells in patients with more advanced hepatocellular carcinoma. Hum Immunol; 2010 Jan;71(1):58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased percentage of B cells in patients with more advanced hepatocellular carcinoma.
  • To compare immunologic phenotypes between (1) hepatocellular carcinoma (HCC) patients and a healthy population and (2) more advanced and early stage HCC patients, we studied 45 HCC patients and 46 healthy controls from January 2006 to January 2008.
  • Most importantly, a higher percentage of B cells was found in patients with advanced HCC than in those with early HCC in terms of TNM stage (II and III vs I, p = 0.004), the Japanese Integrated Scoring system (2-3 vs 0-1, p = 0.0235), and tumor numbers (> or =2 vs 1, p = 0.005).
  • A higher percentage of B cells was found in patients with more advanced HCC compared with patients with early stage HCC, which might serve as an indicator of the severity of HCC.
  • [MeSH-major] B-Lymphocytes / immunology. Carcinoma, Hepatocellular / immunology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Disease Progression. Female. Humans. Killer Cells, Natural / immunology. Leukocytes / immunology. Leukocytes / pathology. Male. Middle Aged. Neoplasm Staging. Phagocytosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19819282.001).
  • [ISSN] 1879-1166
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Nagata H, Hatano E, Asechi H, Narita M, Yanagida A, Yasuchika K, Ikai I, Uemoto S: [Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1]. Gan To Kagaku Ryoho; 2007 Feb;34(2):233-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1].
  • Advanced hepatocellular carcinoma (HCC) with distant metastases, in particular to the lung, has a poor prognosis.
  • This study was undertaken to evaluate the effectiveness of TS-1 as chemotherapy in advanced HCC with lung metastases.
  • Between January 2004 and October 2005, 8 patients with advanced HCC with lung metastasis were enrolled.
  • Randomized controlled trials are necessary to clarify survival benefits in patients with advanced HCC with lung metastasis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / secondary. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Drug Combinations. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301534.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


25. Pereira GH, Mangini C: Treatment of chronic hepatitis C virus infection among Brazilian haemophiliacs. Braz J Infect Dis; 2008 Feb;12(1):20-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic hepatitis C virus (HCV) infection is now the most important cause of liver cirrhosis and hepatocellular carcinoma worldwide.
  • Current treatment reduces the probability of developing advanced stages of liver disease.
  • [MeSH-minor] Adolescent. Adult. Drug Therapy, Combination. Female. Genotype. Hepacivirus / genetics. Humans. Male. Middle Aged. RNA, Viral / analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hemophilia.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18553009.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; 49717AWG6K / Ribavirin
  •  go-up   go-down


26. Francica G, Iodice G, Delle Cave M, Sarrantonio R, Lapiccirella G, Molese V, Smeraldo D, Scarano F, De Marino F: Factors predicting complete necrosis rate after ultrasound-guided percutaneous laser thermoablation of small hepatocellular carcinoma tumors in cirrhotic patients: a multivariate analysis. Acta Radiol; 2007 Jun;48(5):514-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting complete necrosis rate after ultrasound-guided percutaneous laser thermoablation of small hepatocellular carcinoma tumors in cirrhotic patients: a multivariate analysis.
  • MATERIAL AND METHODS: The clinical records of 86 hepatocellular carcinoma (HCC) tumors (mean diameter 23.7 mm) in 60 cirrhotic patients (mean age 68.3 years; 36 males; 57 HCV+; 53 Child's class A, seven Child's class B) treated by means of PLA were reviewed.
  • PLA was performed with a continuous-wave Nd:YAG laser by a single operator who positioned two to four 300-microm optic fibers advanced in 21-gauge needles into target lesions under US guidance.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Laser Coagulation / methods. Liver Cirrhosis / complications. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Necrosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Radiol. 2007 Jun;48(5):473 [17520419.001]
  • (PMID = 17520427.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


27. Li B, Yuan Y, Chen G, He L, Zhang Y, Li J, Li G, Lau WY: Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome? BMC Cancer; 2010;10:535
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?
  • BACKGROUND: Locally advanced (pT3-4N0M0) hepatocellular carcinoma (HCC) is a heterogeneous group of tumors, which consists of four different categories, including HCC with "multiple tumors more than 5 cm", "major vascular invasion", "invasion of adjacent organs", and "perforation of visceral peritoneum".
  • The aim of our study was to verify whether the 2002 version of the Tumor-Node-Metastasis staging system could predict surgical outcomes in patients with locally advanced HCC.
  • Overall survival (OS) and cumulative recurrence rate (CRR) of the four categories of locally advanced HCC patients were compared.
  • RESULTS: In multivariate analysis, major vascular invasion was identified as the most significant factor (HR = 3.291, 95% CI 2.362-4.584, P < 0.001) followed by cirrhosis status on OS, and was found to be the only independent factor of CRR (HR = 2.242, 95% CI 1.811-3.358, P < 0.001) in patients with locally advanced HCC.
  • Among the four categories of locally advanced HCC, OS was significantly worse, and CRR was significantly higher in patients with HCC with major vascular invasion (pT3) than with multiple tumors more than 5 cm (pT3); or tumor invasion of adjacent organs (pT4); or perforation of visceral peritoneum (pT4).
  • There is a need to redefine the T classification and to stratify locally advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Ann Surg. 2007 Jun;245(6):909-22 [17522517.001]
  • [Cites] J Hepatol. 2008;48 Suppl 1:S20-37 [18304676.001]
  • [Cites] Gastroenterology. 2008 Jun;134(7):1908-16 [18549877.001]
  • [Cites] Arch Surg. 2008 Jun;143(6):538-43; discussion 543 [18559745.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Gastrointest Surg. 2008 Sep;12(9):1540-7 [18629593.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1312-27 [18821591.001]
  • [Cites] Eur J Surg Oncol. 2009 Feb;35(2):174-9 [18325724.001]
  • [Cites] Surg Today. 2009;39(10):833-43 [19784720.001]
  • [Cites] Hepatology. 2000 Apr;31(4):864-71 [10733541.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):500-7 [10931448.001]
  • [Cites] J Pathol. 2000 Sep;192(1):43-51 [10951399.001]
  • [Cites] Hepatogastroenterology. 2001 Jan-Feb;48(37):46-50 [11268996.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1527-36 [11896101.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):376-83 [12616122.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):65-75, ix [12735130.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):1078-84 [12845986.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):1-5 [14692017.001]
  • [Cites] Hepatology. 1991 Aug;14(2):262-8 [1650325.001]
  • [Cites] Hepatology. 1992 Jul;16(1):112-7 [1377657.001]
  • [Cites] J Nucl Med. 1994 Nov;35(11):1782-7 [7525901.001]
  • [Cites] Br J Surg. 1995 Feb;82(2):264-6 [7749707.001]
  • [Cites] Surgery. 1996 May;119(5):517-22 [8619206.001]
  • [Cites] Eur J Surg Oncol. 1996 Oct;22(5):516-20 [8903496.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):433-9 [9527067.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):216-22 [10024103.001]
  • [Cites] Surgery. 2005 Apr;137(4):403-10 [15800485.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):364-73 [15915370.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):229-35 [16432356.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2650-5 [17304512.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • (PMID = 20925965.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2958946
  •  go-up   go-down


28. Qun W, Tao Y: Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. Hepatogastroenterology; 2010 May-Jun;57(99-100):426-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
  • Hence, for advanced cholangiocarcinoma, chemotherapy is the only modality left to be chosen.
  • Sorafenib, a multikinase inhibitor, which can competitively inhibit RAF/MEK/ERK pathway, human vascular endothelial growth factor receptors (VEGFR2, VEGFR3) platelet-derived growth factor receptor beta (PDGFR), Flt3, and C-kit receptors, has been successfully applied for solid tumors such as renal cancer and hepatocellular carcinoma.
  • The role of combination with other chemotherapy drugs in advanced cholangiocarcinoma still needs to be defined.
  • [MeSH-minor] Adult. CA-19-9 Antigen / blood. Female. Humans. Infusions, Intra-Arterial. Myeloid Cell Leukemia Sequence 1 Protein. Niacinamide / analogs & derivatives. Phenylurea Compounds. Proto-Oncogene Proteins c-bcl-2 / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698202.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / CA-19-9 Antigen; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


29. Nanashima A, Sumida Y, Abo T, Nagasaki T, Ohba K, Kinoshita H, Tobinaga S, Kenji T, Takeshita H, Hidaka S, Sawai T, Yasutake T, Nagayasu T: Surgical treatment and adjuvant chemotherapy in hepatocellular carcinoma patients with advanced vascular involvement. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):627-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment and adjuvant chemotherapy in hepatocellular carcinoma patients with advanced vascular involvement.
  • BACKGROUND/AIMS: In advanced hepatocellular carcinoma (HCC) with vascular involvement of major vessels, patients have a poor prognosis after surgical treatment.
  • CONCLUSIONS: Complete surgical resection combined with main vascular resection could be safely performed in most advanced stage HCC patients and adjuvant chemotherapy in the early period after resection would be necessary, which may achieve longer survival in some patients even in the advanced stage.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Vascular Neoplasms / drug therapy. Vascular Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613421.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


30. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, Poon RT: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer; 2009 Jan 15;115(2):428-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
  • BACKGROUND: The current study was a phase 2 open-label study to evaluate the efficacy and tolerability of single-agent sorafenib in the treatment of advanced HCC patients in a hepatitis B-endemic Asian population.
  • METHODS: Patients with advanced hepatocellular carcinoma (HCC) received sorafenib at a dose of 400 mg twice daily in 4-week cycles.
  • CONCLUSIONS: Single-agent sorafenib demonstrates good efficacy and acceptable tolerability in treating an advanced HCC patient population in a hepatitis B-endemic area.
  • The presence of lung metastasis predicts poor response to sorafenib in advanced HCC patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatitis B / complications. Liver Neoplasms / drug therapy. Lung Neoplasms / secondary. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Aged. Asian Continental Ancestry Group. Female. Humans. Liver Cirrhosis / complications. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19107763.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


31. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Rentsch M, Muacevic A: Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. Ann Surg Oncol; 2010 Nov;17(11):2877-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The treatment of isolated liver metastases has become a rapidly developing field with many new, technically advanced methods.
  • Four lesions were of primary liver origin (hepatocellular carcinoma and cholangiocellular carcinoma).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20574773.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol; 2005 Feb 10;23(5):965-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
  • This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors.
  • Forty-five patients were assessable for efficacy; one patient had a partial response (hepatocellular carcinoma at 400 mg bid continuous), 25 patients had stable disease, with eight lasting > 6 months and five for >12 months.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Hepatocellular / drug therapy. Cohort Studies. Colonic Neoplasms / drug therapy. Diarrhea / chemically induced. Extracellular Signal-Regulated MAP Kinases / drug effects. Fatigue / chemically induced. Female. Humans. Liver Neoplasms / drug therapy. Lymphocytes / drug effects. Lymphocytes / enzymology. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Phosphorylation / drug effects. Rectal Neoplasms / drug therapy. Safety

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613696.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Phosphatidylethanolamine Binding Protein; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


33. Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK: Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res; 2006 Sep 01;12(17):5207-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
  • EXPERIMENTAL DESIGN: Thirty patients with advanced solid malignancies were treated with 82 courses at six dose levels ranging from 7.8 to 62.2 mg/m2 weekly, initially according to an accelerated dose-escalation scheme, which evolved into a Fibonacci scheme as a relevant degree of toxicity was observed.
  • A patient with non-small cell lung carcinoma experienced a minor response, and a patient with hepatocellular carcinoma had stable disease lasting 11 months.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Depsipeptides / chemistry. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Molecular Structure. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951240.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501019
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; 0 / Oligopeptides; 05G07285DK / tasidotin; 123884-00-4 / dolastatin 15
  •  go-up   go-down


34. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M, Giannini EG, Borzio F, Caturelli E, Chiaramonte M, Bernardi M, Italian Liver Cancer (ITA.LI.CA) Group: Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol; 2010 Aug;53(2):291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.
  • BACKGROUND & AIMS: The current guidelines recommend the surveillance of cirrhotic patients for early diagnosis of hepatocellular carcinoma (HCC), based on liver ultrasonography repetition at either 6 or 12 month intervals, since there is no compelling evidence of superiority of the more stringent program.
  • RESULTS: The cancer stage was less severe in Group 1 than in Group 2 (p<0.001), with more single tiny (2 cm) and less advanced tumors.
  • Age, platelet count, alpha-fetoprotein, Child-Pugh class, cancer stage, and hepatocellular carcinoma treatment were independent prognostic factors.
  • CONCLUSIONS: Semiannual surveillance increases the detection rate of very early hepatocellular carcinomas and reduces the number of advanced tumors as compared to the annual program.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / ultrasonography. Liver Neoplasms / mortality. Liver Neoplasms / ultrasonography. Population Surveillance / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Italy. Liver / ultrasonography. Liver Cirrhosis / complications. Male. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20483497.001).
  • [ISSN] 1600-0641
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Andreone P; Caraceni P; Di Micoli A; Domenicali M; Fatti G; Magalotti D; Zambruni A; Balsamo C; Di Marco M; Vavassori E; Gilardoni L; Mattiello M; Alberti A; Gatta A; Gios M; De Giorgio M; Giacomin A; Gianni S; Rinaldi M; Sergio A; Vanin V; Grazi GL; Pinna AD; Ravaioli M; Giampalma E; Golfieri R; Ghittoni G; Roselli P; Bodini G; Corbo M; Savarino V
  •  go-up   go-down


35. Wang D, Dou K, Xiang H, Song Z, Zhao Q, Chen Y, Li Y: Involvement of RhoA in progression of human hepatocellular carcinoma. J Gastroenterol Hepatol; 2007 Nov;22(11):1916-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of RhoA in progression of human hepatocellular carcinoma.
  • The clinicopathological significance of RhoA, however, is not yet well known in the case of hepatocellular carcinoma (HCC).
  • With regard to venous invasion, satellite lesions and advanced pTNM stage, the RhoA level tended to be higher in HCC than that seen in negative tissue (P < 0.05).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology. rhoA GTP-Binding Protein / analysis
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Polymerase Chain Reaction. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914970.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 124671-05-2 / RHOA protein, human; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


36. Pastorelli D, Cartei G, Zustovich F, Marchese F, Artioli G, Zovato S, Binato S, Ceravolo R, Cingarlini S, Salmaso F, Mattiazzi M, Sanavio C, Farinati F, Zanus G, Cillo U: Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Ann Oncol; 2006 May;17 Suppl 5:v153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.
  • BACKGROUND: Advanced biliary tract cancers have a poor prognosis.
  • Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment.
  • PATIENTS AND METHODS: Clinical trials for biliary and hepatic carcinoma have been reviewed.

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807446.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 25
  •  go-up   go-down


37. Zhao XL, Du J, Zhang SW, Liu YX, Wang X, Sun BC: [A study on vasculogenic mimicry in hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi; 2006 Jan;14(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A study on vasculogenic mimicry in hepatocellular carcinoma].
  • OBJECTIVE: To explore if vasculogenic mimicry (VM) exists in hepatocellular carcinoma (HCC) and to explain the clinical significance of VM.
  • The mean TNM stage of the VM group was not more advanced than that of the non-VM group.
  • [MeSH-major] Carcinoma, Hepatocellular / blood supply. Liver Neoplasms / blood supply. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Microcirculation. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420764.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


38. Cosme A, Montalvo I, Sánchez J, Ojeda E, Torrado J, Zapata E, Bujanda L, Gutiérrez A, Arenas I: [Type III glycogen storage disease associated with hepatocellular carcinoma]. Gastroenterol Hepatol; 2005 Dec;28(10):622-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Type III glycogen storage disease associated with hepatocellular carcinoma].
  • [Transliterated title] Glucogenosis tipo III asociada a carcinoma hepatocelular.
  • We present the case of a 31-year-old woman, diagnosed in childhood with type III glycogen storage disease, who 30 years after onset developed a hepatocellular carcinoma with portal thrombosis in the context of advanced cirrhosis.
  • This is the first case to be reported in the Spanish literature of type III glycogen storage disease associated with hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Liver Neoplasms / etiology
  • [MeSH-minor] Adult. Ascites / etiology. Biomarkers, Tumor / blood. Disease Progression. Fatal Outcome. Female. Glycogen Storage Disease Type III / complications. Humans. Liver Cirrhosis / etiology. Neoplasm Proteins / blood. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Glycogen Storage Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373012.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


39. Liang HL, Huang JS, Lin YH, Lai KH, Yang CF, Pan HB: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma by placing a temporary catheter via the subclavian route. Acta Radiol; 2007 Sep;48(7):734-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma by placing a temporary catheter via the subclavian route.
  • BACKGROUND: A permanent reservoir implantation is considered mandatory for hepatic arterial infusion chemotherapy (HAIC) of hepatocellular carcinoma (HCC).
  • PURPOSE: To evaluate the feasibility of placing a temporary catheter for HAIC in advanced HCC patients.
  • MATERIAL AND METHODS: 25 advanced HCC patients underwent HAIC with drugs delivered from a temporary catheter which was placed percutaneously by puncturing the left subclavian artery under ultrasound guidance.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Catheters, Indwelling. Drug Administration Schedule. Feasibility Studies. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17729003.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


40. Zhang L, Fan WJ, Huang JH, Li CX, Zhao M, Wang LG, Tang T: Comprehensive sequential interventional therapy for hepatocellular carcinoma. Chin Med J (Engl); 2009 Oct 5;122(19):2292-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive sequential interventional therapy for hepatocellular carcinoma.
  • This study aimed to evaluate the effectiveness of comprehensive sequential interventional therapy especially personal therapeutic plan in 53 radical cure patients with hepatocellular carcinoma (HCC).
  • CONCLUSION: Comprehensive sequential interventional therapy especially personal therapeutic plan for HCC play roles in interventional treatment of HCC in middle or advanced stage.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Catheter Ablation. Chemoembolization, Therapeutic. Combined Modality Therapy. Ethanol / administration & dosage. Female. Humans. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonic Therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079128.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


41. Fukai K, Yokosuka O, Imazeki F, Tada M, Mikata R, Miyazaki M, Ochiai T, Saisho H: Methylation status of p14ARF, p15INK4b, and p16INK4a genes in human hepatocellular carcinoma. Liver Int; 2005 Dec;25(6):1209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation status of p14ARF, p15INK4b, and p16INK4a genes in human hepatocellular carcinoma.
  • METHODS: We analyzed the promoter methylation of each gene by methylation-specific PCR in hepatocellular carcinoma (HCC).
  • CONCLUSIONS: The frequent loss of transcription of p16INK4a with promoter methylation not only in the advanced but also in the early stages of HCC suggests that the epigenetic alteration of p16INK4a promoter is likely to be involved in hepatocarcinogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Cyclin-Dependent Kinase Inhibitor p15 / genetics. DNA Methylation. Genes, p16. Liver Neoplasms / genetics. Tumor Suppressor Protein p14ARF / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. Humans. Liver. Male. Middle Aged. Promoter Regions, Genetic / genetics. RNA / analysis. Reverse Transcriptase Polymerase Chain Reaction. Transcriptional Activation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343074.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Tumor Suppressor Protein p14ARF; 63231-63-0 / RNA
  •  go-up   go-down


42. Tangkijvanich P, Thong-Ngam D, Mahachai V, Theamboonlers A, Poovorawan Y: Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol; 2007 Aug 28;13(32):4345-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma.
  • AIM: To determine whether serum interleukin-18 (IL-18) levels correlated with clinicopathologic features and prognosis in patients with hepatocellular carcinoma (HCC).
  • The levels of IL-18 correlated significantly with the presence of venous invasion and advanced tumor stages classified by Okuda's criteria.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Interleukin-18 / blood. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Disease Progression. Female. Humans. Interleukin-12 / blood. Interleukin-6 / blood. Male. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708609.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-18; 0 / Interleukin-6; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC4250862
  •  go-up   go-down


43. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC: Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep; 2008 Apr;19(4):1045-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
  • Hepatocellular carcinoma (HCC) often exhibits an aberrant expression of glycolytic enzymes, particularly type II hexokinase (HKII) and aldolase B (ALDOB).
  • In conclusion, the aberrant expression of ALDOB and HKII is associated with advanced disease, ETR and poor prognosis, and ALDOB down-regulation in stage II HCC is a predictive marker of ETR and an unfavorable outcome.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Fructose-Bisphosphate Aldolase / genetics. Hexokinase / genetics. Liver Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Enzymologic. Genes, p53. Humans. Male. Middle Aged. Mutation. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357395.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.1.1 / Hexokinase; EC 4.1.2.13 / Fructose-Bisphosphate Aldolase
  •  go-up   go-down


44. Kanhere HA, Leopardi LN, Fischer L, Kitchener MI, Maddern GJ: Treatment of unresectable hepatocellular carcinoma with radiolabelled lipiodol. ANZ J Surg; 2008 May;78(5):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of unresectable hepatocellular carcinoma with radiolabelled lipiodol.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common solid organ tumours, with approximately 500,000 new cases being reported each year.
  • CONCLUSION: This study has shown that radiolabelled lipiodol is an effective method for the treatment of unresectable locally advanced HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Iodine Radioisotopes / administration & dosage. Iodized Oil / administration & dosage. Liver Neoplasms / radiotherapy. Radiopharmaceuticals / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatic Artery. Humans. Injections, Intra-Arterial. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ANZ J Surg. 2008 May;78(5):331-2 [18380721.001]
  • (PMID = 18380736.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 8001-40-9 / Iodized Oil
  •  go-up   go-down


45. Guo TK, Hao XY, Ma B, Yang KH, Li YP, Li HL, Gu YH, Cai H, Liu YL, Li Y, Zhan WP: Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol; 2009 Dec;135(12):1685-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
  • PURPOSE: To evaluate the effectiveness of octreotide in advanced hepatocellular carcinoma participants on the basis of randomized controlled trials.
  • Randomized controlled trials of octreotide for advanced hepatocellular carcinoma were selected and evaluated by two investigators.
  • CONCLUSIONS: As for the limitations of the included trials, the result may not demonstrate a significant superiority of octreotide administration in participants with advanced hepatocellular carcinoma from the available evidence.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Octreotide / therapeutic use. Randomized Controlled Trials as Topic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Antineoplastic Agents, Hormonal / therapeutic use. Disease Progression. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1999 Nov;45(5):766-74 [10517918.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Onkologie. 2000 Dec;23(6):597-602 [11441269.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4):333-8 [15758629.001]
  • [Cites] Dig Dis Sci. 2002 Sep;47(9):1953-8 [12353835.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):331-43 [11900219.001]
  • [Cites] Clin Liver Dis. 2001 May;5(2):479-507 [11385973.001]
  • [Cites] Hepatology. 2002 Sep;36(3):687-91 [12198662.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5):514-20 [11685744.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Gut. 1998 Mar;42(3):442-7 [9577356.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S179-88 [15508083.001]
  • [Cites] Trends Endocrinol Metab. 2002 Dec;13(10 ):451-7 [12431842.001]
  • [Cites] Hepatology. 2007 Jan;45(1):9-15 [17187405.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):925-9 [1310435.001]
  • [Cites] Hepatology. 2000 Oct;32(4 Pt 1):842-6 [11003632.001]
  • [Cites] Dig Surg. 2008;25(1):21-6 [18292657.001]
  • [Cites] Semin Gastrointest Dis. 1995 Jul;6(3):148-64 [7551972.001]
  • [Cites] World J Gastroenterol. 2007 Jun 21;13(23):3164-70 [17589893.001]
  • [Cites] Chemotherapy. 2001;47 Suppl 2:1-29 [11275699.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):250-9 [18041064.001]
  • [Cites] Oncology. 1998 Jan-Feb;55(1):39-47 [9428374.001]
  • [Cites] Ann Oncol. 2002 May;13(5):653-68 [12075733.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Chemotherapy. 2001;47 Suppl 2:162-96 [11275709.001]
  • [Cites] Semin Liver Dis. 1999;19(3):271-85 [10518307.001]
  • [Cites] Radiology. 1999 Mar;210(3):655-61 [10207464.001]
  • [Cites] Biopolymers. 2002;66(3):161-83 [12385036.001]
  • [Cites] Hepatology. 2000 Feb;31(2):330-5 [10655254.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):145-51 [8393649.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):707-13 [11584366.001]
  • (PMID = 19536563.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


46. Tseng PL, Tai MH, Huang CC, Wang CC, Lin JW, Hung CH, Chen CH, Wang JH, Lu SN, Lee CM, Changchien CS, Hu TH: Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol; 2008 Oct 1;98(5):349-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients.
  • BACKGROUND AND OBJECTIVES: To elucidate the clinicopathological correlations among vascular endothelial growth factor (VEGF), microvessel density (MVD) and tumor suppressor gene p53 in hepatocellular carcinomas (HCCs), we adopted a new definition of "VEGF overexpression."
  • VEGF overexpression is positively correlated with young age (P = 0.008), male gender (P = 0.01), hepatitis B viremia (P = 0.013), high alpha-fetoprotein levels (P < 0.001), p53 (+) (P = 0.036), advanced-stage HCC (P = 0.015), and HCC dedifferentiation (P = 0.004).
  • Survival analyses indicated that VEGF overexpression, high MVD, and advanced-stage HCC were independent poor prognostic factors for disease-free and overall survival.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. Up-Regulation. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Gene Expression. Genes, p53 / immunology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Sex Factors. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18646041.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / alpha-Fetoproteins
  •  go-up   go-down


47. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taïeb J: Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer; 2007 Apr 1;109(7):1384-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
  • BACKGROUND: New systemic therapies are needed to improve the prognosis of patients with advanced-stage hepatocellular carcinoma (HCC).
  • In a Phase II trial involving previously untreated patients with advanced HCC, the more favorable schedule from a previous pilot study was evaluated.
  • METHODS: Thirty-four patients with previously untreated advanced-stage HCC were prospectively enrolled.
  • CONCLUSIONS: The GEMOX regimen seems to be well tolerated and active in advanced HCC, especially in patients with underlying nonalcoholic liver disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Survival Rate. Treatment Outcome


48. Goodman J, Glasgow SC, Schnitzler M, Lowell JA, Shenoy S, Jendrisak MD, Desai N, Lisker-Melman M, Crippin J, Chapman WC: Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III disease. Arch Surg; 2005 May;140(5):459-64; discussion 464
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III disease.
  • HYPOTHESIS: After liver transplantation, patients with stage III hepatocellular carcinoma (HCC) experience survivals similar to those of patients with less advanced disease and of matched control subjects.
  • RESULTS: From August 1, 1985, to February 28, 2002, we performed 635 adult liver transplantations, including 51 (8%) in patients with HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation


49. Schmid P, Schweigert M, Beinert T, Flath B, Sezer O, Possinger K: Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study. Invest New Drugs; 2005 Mar;23(2):139-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
  • This phase I trial was therefore initiated to determine the optimal dose of gemcitabine administered over 4 h in patients with advanced solid tumors.
  • Objective responses were noted in patients with hepatocellular carcinoma and cholangio-carcinoma.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1991;27(4):258-62 [1998982.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;38(4):335-42 [8674156.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10 [7481842.001]
  • [Cites] Invest New Drugs. 1997;15(4):331-41 [9547676.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1527-31 [8040662.001]
  • [Cites] Anticancer Drugs. 1999 Jul;10(6):525-31 [10885899.001]
  • [Cites] Invest New Drugs. 1998-1999;16(3):275-8 [10360609.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):19-25 [7481840.001]
  • [Cites] Anticancer Drugs. 1995 Dec;6 Suppl 6:27-32 [8718422.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1003-8 [9818075.001]
  • [Cites] Invest New Drugs. 1997;15(2):115-21 [9220290.001]
  • [Cites] Anticancer Drugs. 2001 Oct;12(9):713-7 [11593051.001]
  • [Cites] Anticancer Drugs. 1999 Aug;10(7):625-31 [10507311.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6823-6 [2208147.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):11-8 [7481839.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1309-11 [11106121.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jul;50(1):80-3 [12111116.001]
  • (PMID = 15744590.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


50. Sotiropoulos GC, Malagó M, Bockhorn M, Schmitz KJ, Radtke A, Molmenti EP, Schaffer R, Beckebaum S, Cicinnati VR, Fouzas I, Broelsch CE, Lang H: Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels: is an expansion of the listing criteria justified? Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1671-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels: is an expansion of the listing criteria justified?
  • BACKGROUND: Liver transplantation (LT) is the optimal therapy for hepatocellular carcinoma (HCC) in the setting of cirrhosis.
  • Thirteen patients (25%) demonstrated advanced tumor stages.
  • CONCLUSIONS: HCC patients with AFP values < 30 ng/mL who undergo LT with no bridging treatments experience excellent overall and recurrence-free survival rates, even with advanced tumor stages, independent of the Milan listing criteria.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Cirrhosis / surgery. Liver Neoplasms / surgery. Liver Transplantation. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local


51. Vespasiani Gentilucci U, Perrone G, Galati G, D'Avola D, Zardi EM, Rabitti C, Bianchi A, De Dominicis E, Afeltra A, Picardi A: Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease. Histopathology; 2006 Jun;48(7):822-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To evaluate the cytoplasmic and nuclear expression of hepatic growth hormone receptor (GHR) in different stages (S0, S1, S3 and S4, according to Knodell's classification) of chronic liver disease (CLD) and in hepatocellular carcinoma (HCC).
  • The increase in nuclear expression of GHR with advanced stages of CLD suggests that GH may act directly at the nuclear level to promote hepatocyte proliferation/regeneration.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Hepatitis C, Chronic / pathology. Liver / pathology. Liver Neoplasms / pathology. Receptors, Somatotropin / analysis
  • [MeSH-minor] Adult. Aged. Cell Nucleus / chemistry. Cytoplasm / chemistry. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16722931.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Somatotropin
  •  go-up   go-down


52. Moriyama M, Arakawa Y: Treatment of interferon-alpha for chronic hepatitis C. Expert Opin Pharmacother; 2006 Jun;7(9):1163-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with chronic hepatitis C, IFN-alpha monotherapy results in a significant increase in the cumulative survival rate by suppressing the progression to hepatocellular carcinoma or liver failure.
  • In addition, other efficacious therapeutic regimens have been employed, such as prolonged administration of standard IFN-alpha in elderly patients; prolonged low-dose continuous administration in patients with decompensated cirrhosis or hepatocellular carcinoma postoperative patients; and combination therapy with 5-fluorouracil and standard IFN-alpha for advanced hepatocellular carcinoma.
  • [MeSH-major] Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / prevention & control. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Liver Cirrhosis / drug therapy. Liver Failure / prevention & control. Liver Neoplasms / prevention & control
  • [MeSH-minor] Adult. Clinical Trials as Topic. Drug Administration Schedule. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Polyethylene Glycols / administration & dosage. Polyethylene Glycols / therapeutic use. Recombinant Proteins. Ribavirin / administration & dosage. Ribavirin / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16732703.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 84
  •  go-up   go-down


53. Pierie JP, Muzikansky A, Tanabe KK, Ott MJ: The outcome of surgical resection versus assignment to the liver transplant waiting list for hepatocellular carcinoma. Ann Surg Oncol; 2005 Jul;12(7):552-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of surgical resection versus assignment to the liver transplant waiting list for hepatocellular carcinoma.
  • BACKGROUND: Optimal management of patients with hepatocellular carcinoma (HCC) is controversial.
  • Survival after resection in a group of patients with advanced tumors is worse than that after transplantation; however, shortages of donor livers presently preclude transplantation in this population of patients.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation. Palliative Care
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome. Waiting Lists


54. Kumar R, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK: Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases. QJM; 2008 Jun;101(6):479-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide.
  • Most cases (83%) presented at advanced stage (Okuda III or IV) and cytohistology was the best method to diagnose HCC.
  • CONCLUSION: The prevalence of advanced stage HCC makes most of the detectable lesions unsuitable for curative resection.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Hepatitis B Vaccines / administration & dosage. Hepatitis B, Chronic / complications. Liver Cirrhosis / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. India / epidemiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440958.001).
  • [ISSN] 1460-2393
  • [Journal-full-title] QJM : monthly journal of the Association of Physicians
  • [ISO-abbreviation] QJM
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


55. Han KH, Seong J, Kim JK, Ahn SH, Lee DY, Chon CY: Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer; 2008 Sep 1;113(5):995-1003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis.
  • BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) have a particularly grave prognosis.
  • In the current study, an attempt was made to localize chemoradiation therapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC with PVT and good reserve liver function.
  • CONCLUSIONS: The substantial response rate as well as median survival time noted in the current study encourages the use of this new approach in patients with locally advanced HCC with PVT.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Portal Vein. Venous Thrombosis / etiology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Disease Progression. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Pilot Projects


56. Beaton MD, Adams PC: Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol; 2006 Apr;20(4):257-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nineteen patients (20%) developed hepatocellular carcinoma, one of whom was still living following transplantation.
  • Factors associated with death on multivariate analysis included advanced Child-Pugh score and hepatocellular carcinoma.
  • Patients with hepatocellular carcinoma were older at the time of diagnosis of cirrhosis (mean age 61 and 54.6 years, respectively; P=0.03).
  • The mean age at the time of diagnosis of hepatocellular carcinoma was 70 years (range 48 to 79 years).
  • CONCLUSIONS: Patients with hereditary hemochromatosis and cirrhosis are at significant risk of developing hepatocellular carcinoma.
  • These patients are older when diagnosed with carcinoma and may have poorer survival following transplantation than patients with other causes of liver disease.
  • Early diagnosis and treatment of hereditary hemochromatosis by preventing the development of cirrhosis may reduce the incidence of hepatocellular carcinoma in the future.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Canada / epidemiology. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / pathology. Disease Progression. Female. Follow-Up Studies. Histocompatibility Antigens Class I / genetics. Humans. Liver Neoplasms / etiology. Liver Neoplasms / mortality. Liver Neoplasms / pathology. Male. Membrane Proteins / genetics. Middle Aged. Mutation. Prognosis. Retrospective Studies. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Hemochromatosis.
  • Genetic Alliance. consumer health - Hereditary hemochromatosis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hemochromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Mar;46(3):301-3 [10673284.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):494-503 [16083706.001]
  • [Cites] Gut. 2001 Feb;48(2):251-9 [11156649.001]
  • [Cites] Liver Transpl. 2001 Aug;7(8):663-72 [11510009.001]
  • [Cites] Arch Surg. 2001 Oct;136(10):1177-83 [11585512.001]
  • [Cites] Annu Rev Physiol. 2002;64:663-80 [11826284.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2886-95 [12425564.001]
  • [Cites] Hepatology. 2003 Mar;37(3):520-7 [12601348.001]
  • [Cites] Am J Transplant. 2003 Nov;3(11):1407-12 [14525602.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1897-8 [14667749.001]
  • [Cites] Curr Gastroenterol Rep. 2004 Feb;6(1):44-51 [14720453.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):99-106 [14724442.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jul;1(4):279-84 [15017669.001]
  • [Cites] Am J Transplant. 2004 May;4(5):788-95 [15084176.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1655-62 [15185307.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S104-7 [15508072.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12 [15508073.001]
  • [Cites] Ann Intern Med. 1980 Oct;93(4):519-25 [7436183.001]
  • [Cites] N Engl J Med. 1985 Nov 14;313(20):1256-62 [4058506.001]
  • [Cites] Ann N Y Acad Sci. 1988;526:245-57 [3389643.001]
  • [Cites] Appl Pathol. 1988;6(2):128-38 [2839215.001]
  • [Cites] Adv Intern Med. 1989;34:111-26 [2644754.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):368-72 [2065912.001]
  • [Cites] Hepatology. 1992 Apr;15(4):655-9 [1312985.001]
  • [Cites] Transplantation. 1993 Sep;56(3):554-61 [8212149.001]
  • [Cites] Hepatology. 1994 Dec;20(6):1426-31 [7982640.001]
  • [Cites] Adv Exp Med Biol. 1994;356:293-302 [7887234.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Nat Genet. 1996 Aug;13(4):399-408 [8696333.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):463-72 [9024300.001]
  • [Cites] Liver Transpl Surg. 1995 Jul;1(4):237-41 [9346573.001]
  • [Cites] AJR Am J Roentgenol. 1998 Aug;171(2):433-5 [9694470.001]
  • [Cites] Liver Transpl Surg. 1999 Sep;5(5):369-74 [10477837.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1769-78 [15858186.001]
  • [Cites] Transplantation. 2000 Sep 15;70(5):780-3 [11003357.001]
  • (PMID = 16609753.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2659901
  •  go-up   go-down


57. Zhou L, Rui JA, Wang SB, Chen SG, Qu Q, Chi TY, Wei X, Han K, Zhang N, Zhao HT: Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy. World J Surg; 2007 Sep;31(9):1782-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy.
  • BACKGROUND: Radical major hepatectomy (RMH) has been suggested as one of main options for cure of large/advanced hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Cirrhosis / complications. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Biomarkers, Tumor / blood. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1294-300 [10811342.001]
  • [Cites] Dig Surg. 1999;16(6):459-67 [10805544.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):369-75 [10077049.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S64-8 [14762842.001]
  • [Cites] Am J Surg. 1992 Feb;163(2):246-50 [1739181.001]
  • [Cites] J Gastroenterol Hepatol. 2005 May;20(5):765-71 [15853992.001]
  • [Cites] Arch Surg. 2003 Mar;138(3):265-71 [12611572.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1163-7 [16001653.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2384-90 [11745294.001]
  • [Cites] Arch Surg. 2003 Nov;138(11):1207-13 [14609868.001]
  • [Cites] Eur J Surg. 1999 Jul;165(7):638-46 [10452257.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1766-70 [15532822.001]
  • [Cites] HPB (Oxford). 2002;4(2):99; author reply 99-100 [18332933.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2003 Jul;25(4):404-6 [12921578.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):771-8 [11241245.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):524-9 [15816471.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):299-305 [15273555.001]
  • [Cites] Aust N Z J Surg. 1991 Mar;61(3):201-6 [1848427.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):155-8 [16750027.001]
  • [Cites] Br J Surg. 1996 Jan;83(1):117-20 [8653334.001]
  • [Cites] Am J Surg. 2006 Jul;192(1):29-33 [16769271.001]
  • [Cites] Eur J Surg Oncol. 2006 Sep;32(7):767-72 [16725304.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):1073-7 [12845985.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):63-70 [11420484.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):401-6 [10228830.001]
  • [Cites] Eur J Surg. 1999 May;165(5):446-53 [10391161.001]
  • [Cites] Ann Surg. 1983 Apr;197(4):375-88 [6299217.001]
  • [Cites] Ann Surg. 2000 Nov;232(5):665-72 [11066138.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):51-63 [12735129.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):183-9 [12555294.001]
  • [Cites] J Am Coll Surg. 2004 Mar;198(3):356-65 [14992736.001]
  • [Cites] Hepatogastroenterology. 2003 Mar-Apr;50(50):475-9 [12749251.001]
  • (PMID = 17610113.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


58. Jacqueminet S, Lebray P, Morra R, Munteanu M, Devers L, Messous D, Bernard M, Hartemann-Heurtier A, Imbert-Bismut F, Ratziu V, Grimaldi A, Poynard T: Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol; 2008 Jul;6(7):828-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Patients with diabetes are at risk for nonalcoholic fatty liver disease leading to advanced fibrosis, cirrhosis, and liver cancer.
  • The biomarker data were obtained, and patients with presumed advanced fibrosis were reinvestigated by a hepatologist using elastography and, if necessary, ultrasonography, endoscopy, or liver biopsy.
  • RESULTS: The biomarker predicted advanced fibrosis in 63 of 1131 (5.6%) patients.
  • A total of 45 patients was reinvestigated, and advanced fibrosis was confirmed in 32 patients, a 2.8% (32/1131) prevalence of confirmed advanced fibrosis, 5 cases of cirrhosis, and 4 cases of hepatocellular carcinoma.
  • In the population with type 2 diabetes who were 45 years or older, the prevalence of confirmed advanced fibrosis was 4.3% (30/696), and hepatocellular carcinoma was 5.7 of 1000 (4/696).
  • CONCLUSIONS: The fibrosis biomarker might be used for the detection of advanced fibrosis in patients with type 2 diabetes.
  • [MeSH-minor] Adult. Aged. Biomarkers. Biopsy. Elasticity Imaging Techniques. Endoscopy. Female. Humans. Liver / pathology. Male. Middle Aged. Prevalence. Prospective Studies. Severity of Illness Index. Ultrasonography

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18524692.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


59. Uhm JE, Park JO, Lee J, Park YS, Park SH, Yoo BC, Paik SW, Koh KC, Kang WK, Lim HY: A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol; 2009 Apr;63(5):929-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
  • CONCLUSIONS: The combination of oxaliplatin and doxorubicin showed modest activity and a tolerable toxicity profile in advanced HCC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Doxorubicin / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726098.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 80168379AG / Doxorubicin
  •  go-up   go-down


60. Yamazaki Y, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, Abe T, Katakai K, Kojima A, Matsuzaki Y, Mori M: Hepatocellular carcinoma in young adults: the clinical characteristics, prognosis, and findings of a patient survival analysis. Dig Dis Sci; 2007 Apr;52(4):1103-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in young adults: the clinical characteristics, prognosis, and findings of a patient survival analysis.
  • Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide.
  • Because most of the patients did not receive periodic follow-up, this disease often was discovered at an advanced stage, usually after the appearance of some symptoms.
  • Young patients with HCC tended to have a poor prognosis because of advanced stage of HCC, despite a well-preserved liver function and aggressive treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Female. Hepatitis B Surface Antigens / analysis. Hepatitis C Antibodies / analysis. Humans. Japan. Male. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1516-25 [6311397.001]
  • [Cites] Cancer. 1990 Dec 1;66(11):2395-8 [2173972.001]
  • [Cites] Hepatogastroenterology. 2005 Nov-Dec;52(66):1795-7 [16334779.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):903-7 [15966229.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1510-5 [6311396.001]
  • [Cites] Cancer. 1980 Sep 15;46(6):1448-55 [6251961.001]
  • (PMID = 17380407.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Hepatitis C Antibodies
  •  go-up   go-down


61. Noophun P, Kongkam P, Gonlachanvit S, Rerknimitr R: Bleeding gastric varices: results of endoscopic injection with cyanoacrylate at King Chulalongkorn Memorial Hospital. World J Gastroenterol; 2005 Dec 21;11(47):7531-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced cirrhosis and hepatocellular carcinoma (HCC) were major risk factors for uncontrolled bleeding.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Thailand. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Gastroenterol. 2006 Sep 14;12(34):5587 [17007008.001]
  • (PMID = 16437729.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyanoacrylates; 0 / Tissue Adhesives
  • [Other-IDs] NLM/ PMC4725170
  •  go-up   go-down


62. Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, Sakaguchi H, Kuroda T, Kioka K, Kim SR, Kanno T, Ueda T, Hirano M, Fujimoto S, Jomura H, Nishiguchi S, Seki S: Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int; 2007 Mar;27(2):186-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
  • BACKGROUND: Interferon (IFN) improves hepatic inflammation/fibrosis and reduces the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CH-C).
  • As compared with SVR patients without HCC, SVR patients with HCC were predominantly male (P=0.003), older at the initiation of IFN therapy (P=0.002), and at a more advanced histologic stage of disease (P<0.001).
  • CONCLUSIONS: SVR patients with CH-C who are elderly, male, or have an advanced histologic stage are at a high risk for the development of HCC after IFN therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / virology. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / drug therapy. Interferons / therapeutic use. Liver Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Cohort Development.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17311612.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 9008-11-1 / Interferons
  •  go-up   go-down


63. Chen ZS, He F, Zeng FJ, Jiang JP, Du DF, Liu B: Early steroid withdrawal after liver transplantation for hepatocellular carcinoma. World J Gastroenterol; 2007 Oct 21;13(39):5273-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early steroid withdrawal after liver transplantation for hepatocellular carcinoma.
  • AIM: To evaluate the impact of early steroid withdrawal on the incidence of rejection, tumor recurrence and complications after liver transplantation for advanced-stage hepatocellular carcinoma.
  • METHODS: Fifty-four patients underwent liver transplantation for advanced-stage hepatocellular carcinoma from April 2003 to June 2005.
  • The incidence of rejection, 6-mo and 1-year recurrence rate of carcinoma, 1-year survival rate, mean serum tacrolimus trough level, and liver and kidney function were compared between the two groups.
  • RESULTS: In the two groups, no statistical difference was observed in the incidence of rejection (14.3 vs 11.5%, P > 0.05), mean serum tacrolimus trough levels (6.9 +/- 1.4 vs 7.1 +/- 1.1 microg/L, P > 0.05), liver and kidney function after 6 mo [alanine aminotransferase (ALT): 533 +/- 183 vs 617 +/- 217 nka/L, P > 0.05; creatinine: 66 +/- 18 vs 71 +/- 19 micromol/L, P > 0.05], 6-mo recurrence rate of carcinoma (25.0 vs 42.3%, P > 0.05), and 1-year survival rate (64.2 vs 46.1%, P > 0.05).
  • CONCLUSION: Early steroid withdrawal was safe after liver transplantation in patients with advanced-stage hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / etiology. Liver Neoplasms / surgery. Liver Transplantation. Steroids / administration & dosage
  • [MeSH-minor] Adult. Female. Graft Rejection / prevention & control. Humans. Immunosuppressive Agents / blood. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Survival Rate. Tacrolimus / blood. Tacrolimus / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876900.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Steroids; WM0HAQ4WNM / Tacrolimus
  • [Other-IDs] NLM/ PMC4171311
  •  go-up   go-down


64. Lin YS, Jung SM, Tsai FC, Yeh CN, Shiu TF, Wu HH, Lin PJ, Chu PH: Hepatoma with cardiac metastasis: an advanced cancer requiring advanced treatment. World J Gastroenterol; 2007 Jul 7;13(25):3513-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoma with cardiac metastasis: an advanced cancer requiring advanced treatment.
  • AIM: To investigate the clinical and pathologic findings, and to discuss the pathophysiology of hepatocellular carcinoma with cardiac metastasis.
  • METHODS: Eight hepatoma patients with cardiac metastasis, who were treated by surgical excision from 1993 to 2006, were retrospectively studied.
  • CONCLUSION: Hepatoma metastasis to the heart was detected in all eight patients.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Heart Neoplasms / secondary. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1259-62 [15362727.001]
  • [Cites] Int J Clin Pract. 2004 Jun;58(6):564-7 [15311555.001]
  • [Cites] Gastroenterology. 1986 Feb;90(2):289-98 [2416627.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]
  • [Cites] Virchows Arch. 2005 Jan;446(1):52-5 [15568157.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):212-6 [15783033.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):822-7 [15696123.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):425-9 [16012295.001]
  • [Cites] World J Surg. 2005 Jun;29(6):715-8 [16078127.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7 [16246200.001]
  • [Cites] Eur J Cancer. 2000 Jan;36(2):151-69 [10741273.001]
  • [Cites] Chang Gung Med J. 2001 Feb;24(2):97-102 [11360408.001]
  • [Cites] J Am Soc Echocardiogr. 2004 Feb;17(2):192-4 [14752497.001]
  • [Cites] Int J Clin Pract. 2004 Mar;58(3):306-9 [15117101.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):497-513 [15205947.001]
  • [Cites] Acta Pathol Jpn. 1984 Jul;34(4):839-45 [6091401.001]
  • (PMID = 17659700.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Other-IDs] NLM/ PMC4146789
  •  go-up   go-down


65. Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, Toyota N, Ito K, Chayama K: Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol; 2007 Oct;42(10):845-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
  • BACKGROUND: Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT).
  • CONCLUSIONS: HCV antibody positivity may be a significant pretreatment predictor of early response, TTP, and survival of patients with advanced HCC treated with 5-FU/IFN.
  • CR or PR as the early response to the combination therapy might indicate a more favorable prognosis in patients with advanced HCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepatitis C Antibodies / blood. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Disease Progression. Female. Fluorouracil / administration & dosage. Forecasting. Humans. Infusions, Intra-Arterial. Interferon-alpha / administration & dosage. Male. Middle Aged. Portal Vein / pathology. Prognosis. Recombinant Proteins. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome. Venous Thrombosis / complications

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Jan;29(1):62-7 [9862851.001]
  • [Cites] Ann Clin Lab Sci. 2006 Spring;36(2):144-50 [16682509.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):435-42 [11900229.001]
  • [Cites] Cancer. 1997 May 15;79(10):1890-6 [9149014.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2087-94 [9179054.001]
  • [Cites] Scand J Gastroenterol. 2003 Aug;38(8):894-900 [12940445.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2666-70 [14669309.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1206-13 [17287900.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):588-95 [12209752.001]
  • [Cites] Am J Surg. 2002 Sep;184(3):284-90 [12354601.001]
  • [Cites] Cancer Res. 1987 Sep 15;47(18):4967-72 [3040235.001]
  • [Cites] World J Gastroenterol. 2007 Jan 21;13(3):414-20 [17230611.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1209-16 [17919232.001]
  • [Cites] J Med Virol. 2006 Apr;78(4):459-65 [16482557.001]
  • [Cites] Br J Cancer. 2005 Sep 5;93(5):557-64 [16106266.001]
  • [Cites] Annu Rev Med. 1994;45:297-323 [8198385.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Ann Surg. 1988 Jul;208(1):23-35 [2839123.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S17-26 [15508082.001]
  • [Cites] Oncology. 1998 Jan-Feb;55(1):39-47 [9428374.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Dec;9(12):1841-50 [6319339.001]
  • [Cites] Cancer. 2006 May 1;106(9):1990-7 [16565970.001]
  • [Cites] Biomed Pharmacother. 1998;52(1):34-43 [9755793.001]
  • [Cites] Hepatology. 1998 Sep;28(3):751-5 [9731568.001]
  • [Cites] Cancer. 1988 May 15;61(10):1983-7 [2834036.001]
  • (PMID = 17940838.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hepatitis C Antibodies; 0 / Interferon-alpha; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b; U3P01618RT / Fluorouracil
  •  go-up   go-down


66. Yuan RH, Jeng YM, Chen HL, Hsieh FJ, Yang CY, Lee PH, Hsu HC: Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis. Clin Cancer Res; 2005 Apr 1;11(7):2568-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis.
  • This study is to investigate the clinicopathologic denotation of their expression in hepatocellular carcinoma (HCC).
  • CONCLUSIONS: These data suggest that PAP expression designate a subset of low-grade, low-stage HCC with frequent beta-catenin mutation and hence more favorable prognosis, whereas further genetic or epigenetic alterations, such as p53 mutation and REG1A expression, lead to more advanced HCCs.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Calcium-Binding Proteins / genetics. Carcinoma, Hepatocellular / pathology. Lectins, C-Type / genetics. Liver Neoplasms / pathology. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cytoskeletal Proteins / genetics. Disease Progression. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Lithostathine. Male. Middle Aged. Mutation. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Survival Analysis. Trans-Activators / genetics. Tumor Suppressor Protein p53 / genetics. beta Catenin

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814635.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Calcium-Binding Proteins; 0 / Cytoskeletal Proteins; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / Nerve Tissue Proteins; 0 / REG1A protein, human; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; 0 / pancreatitis-associated protein
  •  go-up   go-down


67. Lang H, Sotiropoulos GC, Frühauf NR, Dömland M, Paul A, Kind EM, Malagó M, Broelsch CE: Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg; 2005 Jan;241(1):134-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period.
  • OBJECTIVE: To evaluate the role of extended hepatectomy in locally advanced intrahepatic cholangiocarcinoma (ICC).
  • SUMMARY BACKGROUND DATA: ICC is a rare tumor which has to be clearly distinguished from hepatocellular carcinoma and extrahepatic bile duct carcinoma.
  • METHODS: Between April 1998 and March 2003, 50 patients with locally advanced ICC (tumor involvement of more than 4 liver segments) underwent surgical exploration.
  • CONCLUSIONS: R0-resection can provide prolonged survival, even in patients with advanced ICC.
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Surgical Procedures, Operative / methods. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):117-21 [10398897.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):365-72 [9783782.001]
  • [Cites] Lancet. 2000 Mar 4;355(9206):807-8 [10711932.001]
  • [Cites] Surgery. 2000 May;127(5):498-505 [10819057.001]
  • [Cites] Transplantation. 2000 Apr 27;69(8):1633-7 [10836374.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1182-7 [10971425.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1353-7 [11391522.001]
  • [Cites] J Am Coll Surg. 2001 Oct;193(4):384-91 [11584966.001]
  • [Cites] Br J Surg. 2001 Nov;88(11):1463-6 [11683741.001]
  • [Cites] Liver Transpl. 2001 Dec;7(12):1023-33 [11753904.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1 [12049538.001]
  • [Cites] Ultrasound Med Biol. 2002 Apr;28(4):439-44 [12049956.001]
  • [Cites] World J Surg. 2002 Jun;26(6):687-93 [12053220.001]
  • [Cites] Am J Surg. 2002 Jun;183(6):679-85 [12095601.001]
  • [Cites] Surgery. 1992 Jun;111(6):617-22 [1317612.001]
  • [Cites] Br J Surg. 1993 Jul;80(7):903-6 [8369932.001]
  • [Cites] Am J Surg. 1993 Dec;166(6):768-71; discussion 771-2 [8273866.001]
  • [Cites] Ann Surg. 1994 Dec;220(6):711-9 [7986136.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):83-8 [7740815.001]
  • [Cites] Arch Surg. 1995 Oct;130(10):1073-8 [7575119.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):463-73; discussion 473-5 [8857851.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1517-21 [9014664.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):301-5; discussion 305-6 [9015175.001]
  • [Cites] J Surg Oncol. 1997 Jan;64(1):63-7 [9040803.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):947-54 [9060532.001]
  • [Cites] Hepatogastroenterology. 1997 May-Jun;44(15):760-5 [9222685.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):429-36 [9358085.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):70-9 [9445113.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):41-7 [9683753.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1068-70 [9717998.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1206-9 [9752860.001]
  • [Cites] N Engl J Med. 1999 Oct 28;341(18):1368-78 [10536130.001]
  • (PMID = 15622001.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1356856
  •  go-up   go-down


68. Yang ZQ, Yang ZY, Zhang LD, Ping-Bie, Wang SG, Ma KS, Li XW, Dong JH: Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients. Hum Immunol; 2010 Dec;71(12):1180-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients.
  • Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, and patients who are diagnosed with this tumor typically have a poor prognosis.
  • Most importantly, a higher percentage of intrahepatic CD8(+)FoxP3(+) regulatory T cells was found in patients with advanced HCC than in those with early HCC in terms of tumor-node-metastasis (TNM) stage (stage I vs III, p = 0.0007).
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Carcinoma, Hepatocellular / pathology. Forkhead Transcription Factors / metabolism. Liver Neoplasms / pathology. Lymphocytes, Tumor-Infiltrating. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Liver / immunology. Liver / pathology. Lymphocyte Activation. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20870003.001).
  • [ISSN] 1879-1166
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


69. Kim DY: Which treatment modality should we choose for advanced hepatocellular carcinoma? Korean J Hepatol; 2010 Dec;16(4):353-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Which treatment modality should we choose for advanced hepatocellular carcinoma?
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Benzenesulfonates / administration & dosage. Chemoembolization, Therapeutic. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / administration & dosage. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Surg Oncol. 2002 Jul;80(3):143-8 [12115797.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1734-9 [12049862.001]
  • [Cites] Semin Liver Dis. 1999;19(3):329-38 [10518312.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1532-8 [16234567.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):588-95 [12209752.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25 [17103105.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):129-37 [17508408.001]
  • [Cites] Cancer. 2008 Sep 1;113(5):995-1003 [18615601.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Jan;65(2):373-82 [19763572.001]
  • [Cites] Korean J Hepatol. 2010 Dec;16(4):355-61 [21415578.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):460-7 [20888138.001]
  • [CommentOn] Korean J Hepatol. 2010 Dec;16(4):355-61 [21415578.001]
  • (PMID = 21415577.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC3304607
  •  go-up   go-down


70. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL: Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother; 2005 Mar-Apr;28(2):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma.
  • A phase 1 study was conducted to assess the safety and immunologic response induced by direct injection of autologous immature dendritic cells (DCs) into tumor under radiotherapy in advanced hepatoma patients.
  • Patients with advanced/metastatic stage hepatoma not suitable for surgery or transarterial embolization were enrolled.
  • [MeSH-major] Cancer Vaccines. Carcinoma, Hepatocellular / radiotherapy. Combined Modality Therapy. Dendritic Cells / cytology. Immunotherapy / methods. Immunotherapy, Adoptive / methods. Liver Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Autoimmune Diseases. Cohort Studies. Cytokines / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Injections, Intralesional. Interferon-gamma / metabolism. K562 Cells. Killer Cells, Natural / cytology. Male. Middle Aged. Neoplasm Metastasis. Time Factors. Tomography, X-Ray Computed. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725956.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines; 0 / alpha-Fetoproteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


71. Chen MH, Yan K, Yang W, Gao W, Dai Y, Huo L, Zhang H, Huang XF: [Long term (5 years) outcome of radiofrequency ablation for hepatocellular carcinoma in 256 cases]. Beijing Da Xue Xue Bao; 2005 Dec 18;37(6):671-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long term (5 years) outcome of radiofrequency ablation for hepatocellular carcinoma in 256 cases].
  • A total of 267 patients with hepatocellular carcinoma underwent ultrasound-guided radiofrequency ablation (RFA) in Peking University School of Oncology between 1999 and 2005 (421 RFA sessions).
  • In conclusion, RFA with standard protocol has evolved as a minimally invasive local treatment that could achieve satisfactory outcomes for small liver tumors, and has become an effective and relatively safe alternative for the treatment of advanced tumors and recurrent tumors, which are not suitable for traditional therapy.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation / methods. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16378128.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


72. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, Zhao QC, Tian R, Feng Q, Zhang SH, Li Y, Jiang JL, Li L, Yu XL, Zhang Z, Chen ZN: A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology; 2007 Feb;45(2):269-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation.
  • Here, we reported a randomized controlled trial to assess the post-OLT antirecurrence efficacy of Licartin in advanced HCC patients.
  • CONCLUSION: Licartin is a promising drug for preventing post-OLT tumor recurrence in advanced HCC patients excluded by the currently strict criteria for OLT.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Liver Transplantation. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Antigens, CD147 / immunology. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Single-Blind Method. Survival Rate. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2007 Jul;13(7):1057-8 [17600354.001]
  • [CommentIn] Hepatology. 2007 Feb;45(2):263-5 [17256762.001]
  • (PMID = 17256759.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / BSG protein, human; 0 / alpha-Fetoproteins; 0 / metuximab; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


73. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL: Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol; 2009 Aug;10(8):794-800
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
  • BACKGROUND: Hepatocellular carcinoma (HCC) tumour spread is partly dependent on neoangiogenesis.
  • In this open-label, multicentre, phase II trial done in Europe and Asia, sunitinib, a multitargeted tyrosine-kinase inhibitor with anti-angiogenic properties, was assessed in patients with advanced unresectable HCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Indoles / therapeutic use. Liver Neoplasms / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Aug;10(8):743-4 [19647195.001]
  • (PMID = 19586800.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00247676
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


74. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF: Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother; 2005 Sep-Oct;28(5):496-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial.
  • Hepatocellular carcinoma (HCC) is a common and rapidly progressing malignancy.
  • Current treatment options for advanced HCC are limited.
  • This clinical study of dendritic cell (DC)-based immunotherapy for HCC enrolled 31 patients with advanced HCC.
  • In this trial, DC vaccinations for advanced HCC were safe.
  • Pulsed DC vaccination followed by boosters can provide better clinical survival for advanced HCC patients than pulsed DC vaccination only.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Dendritic Cells / cytology. Immunotherapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cancer Vaccines. Cell Membrane / metabolism. Cytokines / metabolism. Disease Progression. Female. Humans. Hypersensitivity, Delayed. Immunotherapy, Adoptive / methods. Lymphocytes / metabolism. Male. Middle Aged. Monocytes / cytology. Phenotype. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16113606.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines
  •  go-up   go-down


75. Abbasi A, Butt N, Bhutto AR, Munir SM: Correlation of thrombocytopenia with grading of esophageal varices in chronic liver disease patients. J Coll Physicians Surg Pak; 2010 Jun;20(6):369-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patient with advanced cirrhosis (Child-Pugh class C), human immunodeficiency virus (HIV) infection, hepatocellular carcinoma, portal vein thrombosis, parenteral drug addiction, current alcohol abuse and previous or current treatment with b-blockers, diuretics and other vasoactive drugs were excluded from the study.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Chronic Disease. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Severity of Illness Index. Young Adult

  • Genetic Alliance. consumer health - Esophageal Varices.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20642964.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


76. Vigano L, Laurent A, Tayar C, Tomatis M, Ponti A, Cherqui D: The learning curve in laparoscopic liver resection: improved feasibility and reproducibility. Ann Surg; 2009 Nov;250(5):772-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Proportion of LLR progressively increased (17.5%, 22.4%, and 24.2%), such as hepatocellular carcinoma (17.6%, 25.6%, and 39.4%, P < 0.05), colorectal metastases (0%, 6.5%, and 13.1%, P < 0.05), major hepatectomies (1.1%, 9.1%, 8.5%, P < 0.05), and right hepatectomies (0%, 13.2%, and 13.1%, P < 0.05).
  • The learning curve demonstrated in this study suggests that LLR is reproducible in liver units but specific training to advanced laparoscopy is required.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / surgery. Male. Middle Aged. Reoperation. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801926.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T: Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol; 2007 Nov 7;13(41):5465-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study.
  • AIM: To investigate the poor prognosis of HCC with PVTT, we evaluated the efficacy by a new combination chemotherapy for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
  • CONCLUSION: Although the prognosis of most patients with Stage IVA HCC by PVTT is poor, our combination chemotherapy may induces long-term survival and is an effective treatment and produced anti-tumor activity with tolerable adverse effects in patients for advanced Stage IVA HCC accompanied by PVTT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Chemotherapy, Cancer, Regional Perfusion. Liver Neoplasms / drug therapy. Portal Vein. Venous Thrombosis / etiology
  • [MeSH-minor] Administration, Oral. Adult. Aged. Carboplatin / administration & dosage. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prospective Studies. Severity of Illness Index. Tablets, Enteric-Coated. Tegafur / administration & dosage. Time Factors. Treatment Outcome. Uracil / administration & dosage


78. Kubo F, Ueno S, Hiwatashi K, Sakoda M, Kawaida K, Nuruki K, Aikou T: Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol; 2005 Oct;12(10):800-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis.
  • BACKGROUND: Angiogenic factor seems necessary for the development of hepatocellular carcinoma (HCC), which is a hypervascular malignancy.
  • [MeSH-major] Carcinoma, Hepatocellular / blood supply. Carcinoma, Hepatocellular / physiopathology. Interleukin-8 / biosynthesis. Interleukin-8 / physiology. Liver Neoplasms / blood supply. Liver Neoplasms / physiopathology. Neovascularization, Pathologic
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Chemotaxis. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132378.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8
  •  go-up   go-down


79. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C, HENCORE Group: Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat; 2007 Aug;14(8):556-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of decompensated cirrhosis, hepatocellular carcinoma (HCC) and liver transplantation was analysed in relation to different host and viral factors.
  • Advanced age at infection and presence of the human leucocyte antigen (HLA) DRB1*1201-3 allele were possibly associated with a higher rate of progression to decompensated cirrhosis or HCC.
  • Advanced age at inclusion, advanced age at infection, viral genotype 1, non-response to previous therapy and possibly some specific HLA alleles are factors independently associated with a faster rate of progression towards liver complications.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Hepacivirus / growth & development. Hepatitis C / complications. Liver Cirrhosis / virology. Liver Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Disease Progression. Female. Follow-Up Studies. Histocytochemistry. Humans. Male. Middle Aged


80. Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, Kodama H, Shirakawa H, Kawakami Y, Takahashi S, Toyota N, Ito K, Chayama K: Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int; 2007 Nov;27(9):1209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
  • AIM: Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cost-Benefit Analysis. Disease-Free Survival. Drug Therapy, Combination. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Prognosis. Prospective Studies. Recombinant Proteins. Survival Rate. Therapeutic Equivalency

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919232.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b; U3P01618RT / Fluorouracil
  •  go-up   go-down


81. Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M: Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology; 2006 Oct;44(4):891-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial.
  • Frequent recurrence of hepatocellular carcinoma (HCC) after surgery remains a major clinical problem.
  • The proportion of patients with advanced recurrence (i.e., multiple, extrahepatic, or associated with vascular invasion) was significantly higher in the UFT group (74%, 43 of 58 patients with recurrence) than in the control group (53%, 30 of 57) (P = .02).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control. Tegafur / administration & dosage. Uracil / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006925.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


82. Miyayama S, Matsui O, Taki K, Minami T, Ryu Y, Ito C, Nakamura K, Inoue D, Notsumata K, Toya D, Tanaka N, Mitsui T: Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization. Cardiovasc Intervent Radiol; 2006 Jan-Feb;29(1):39-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization.
  • PURPOSE: To evaluate the incidence of each extrahepatic collateral pathway to hepatocellular carcinoma (HCC) and to assess technical success rates and complications of transcatheter arterial chemoembolization (TACE) through each collateral.
  • TACE through extrahepatic collaterals using iodized oil and gelatin sponge particles was performed when a catheter was advanced into the tumor-feeding branch to avoid nontarget embolization.
  • [MeSH-major] Carcinoma, Hepatocellular / blood supply. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / blood supply. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiography. Collateral Circulation. Female. Humans. Iodized Oil / administration & dosage. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328697.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8001-40-9 / Iodized Oil
  •  go-up   go-down


83. Funagayama M, Kondo K, Chijiiwa K, Kataoka H: Expression of hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma and postoperative outcomes. World J Surg; 2010 Jul;34(7):1563-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma and postoperative outcomes.
  • HAI-1 is expressed in hepatocellular carcinoma (HCC) to various degrees.
  • HAI-1 positivity related to multiplicity, vascular invasion, and characteristics of advanced tumor stage.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Proteinase Inhibitory Proteins, Secretory / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytotechnology. 1992;8(3):219-29 [1368819.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1101-5 [12615728.001]
  • [Cites] FEBS Lett. 2005 Mar 28;579(9):1945-50 [15792801.001]
  • [Cites] Lancet. 1999 Mar 6;353(9155):797-801 [10459961.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2223-9 [18642042.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9577-82 [8790372.001]
  • [Cites] J Hepatol. 1999 Mar;30(3):511-8 [10190737.001]
  • [Cites] Hepatology. 1996 Jul;24(1):60-4 [8707284.001]
  • [Cites] J Gastroenterol. 2002 Nov;37 Suppl 14:15-21 [12572861.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S218-24 [15508087.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1423-35 [15521012.001]
  • [Cites] J Biol Chem. 1993 Oct 25;268(30):22927-32 [8226803.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):255-66 [15972969.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):223-36 [12784998.001]
  • [Cites] J Histochem Cytochem. 1999 May;47(5):673-82 [10219059.001]
  • [Cites] Histopathology. 2006 Oct;49(4):388-95 [16978202.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(5):399-404 [16258809.001]
  • [Cites] Hepatology. 2009 Feb;49(2):491-503 [19065669.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1050-5 [8635122.001]
  • [Cites] Liver Int. 2006 Sep;26(7):774-80 [16911458.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Aug;289(2):C462-70 [15800053.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1574-9 [15014006.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 23;289(1):205-11 [11708800.001]
  • [Cites] Cancer. 1988 Apr 15;61(8):1621-8 [2450634.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):10-24 [10862190.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1115-25 [8622656.001]
  • [Cites] Carcinogenesis. 1995 Apr;16(4):841-3 [7728965.001]
  • [Cites] Ann Surg. 1990 Mar;211(3):277-87 [2155591.001]
  • [Cites] Hepatology. 1994 Nov;20(5):1231-6 [7927256.001]
  • [Cites] J Biol Chem. 2000 Dec 22;275(51):40453-62 [11013244.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):655-9 [9472107.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6370-6 [9045658.001]
  • [Cites] Cancer Lett. 2005 Sep 8;227(1):83-93 [16051034.001]
  • [Cites] Hepatogastroenterology. 1999 Sep-Oct;46(29):2931-4 [10576375.001]
  • [Cites] Hepatology. 1997 Apr;25(4):862-6 [9096589.001]
  • (PMID = 20213201.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINT1 protein, human
  •  go-up   go-down


84. Nakamura S, Nouso K, Noguchi Y, Higashi T, Ono T, Jungbluth A, Chen YT, Old LJ, Nakayama E, Shiratori Y: Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol; 2006 Aug;21(8):1281-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma.
  • BACKGROUND AND AIM: The present study was designed to investigate the expression of and humoral response against NY-ESO-1 in patients with hepatocellular carcinoma and to analyze the relationship between expression of NY-ESO-1 mRNA and clinicopathological features.
  • METHODS: NY-ESO-1 mRNA and protein expression in surgically resected hepatocellular carcinoma specimens, adjacent non-cancerous liver and non-tumor bearing liver were examined by reverse transcription-polymerase chain reaction and immunohistochemical staining using a monoclonal antibody against NY-ESO-1 (ES121), respectively.
  • RESULTS: NY-ESO-1 mRNA was detected in 18 of 41 (43.9%) hepatocellular carcinomas.
  • Immunohistochemistry revealed heterogeneous expression of NY-ESO-1 protein in three of 18 NY-ESO-1 mRNA-positive hepatocellular carcinomas.
  • None of 23 NY-ESO-1 mRNA-negative hepatocellular carcinomas expressed NY-ESO-1 protein.
  • Antibody against NY-ESO-1 protein was detected in two of 92 patients with hepatocellular carcinoma.
  • CONCLUSIONS: The present study has demonstrated the expression of NY-ESO-1 mRNA in hepatocellular carcinoma and NY-ESO-1 antibody production in patients with advanced hepatocellular carcinoma.
  • Although the enhancement of NY-ESO-1 protein expression and the activation of immune response of the patients with hepatocellular carcinoma are necessary, NY-ESO-1 has the potential to be a good target molecule for immunotherapy against advanced hepatocellular carcinoma.
  • [MeSH-major] Antigens, Neoplasm / genetics. Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Membrane Proteins / genetics
  • [MeSH-minor] Adult. Aged. DNA, Neoplasm / analysis. Female. Gene Expression. Humans. Immunohistochemistry. Liver / pathology. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872310.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / DNA, Neoplasm; 0 / Membrane Proteins
  •  go-up   go-down


85. Tsai FC, Liu CJ, Chen CL, Chen PJ, Lai MY, Kao JH, Chen DS: Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. J Viral Hepat; 2007 Mar;14(3):153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma.
  • Advanced age and high hepatitis B virus (HBV) DNA level are risk factors associated with the development of HBV-related hepatocellular carcinoma (HCC).
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Carrier State / virology. Hepatitis B / complications. Hepatitis B / virology. Hepatitis B virus / physiology. Liver Neoplasms / virology. Serum / virology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Alanine Transaminase / blood. DNA, Viral / blood. Female. Genotype. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Risk Factors. Statistics as Topic. Viral Load

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305880.001).
  • [ISSN] 1352-0504
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


86. Helling TS, Woodall CE 3rd: Referrals for surgical therapy in patients with hepatocellular carcinoma: a community experience. J Gastrointest Surg; 2007 Jan;11(1):76-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Referrals for surgical therapy in patients with hepatocellular carcinoma: a community experience.
  • The treatment of hepatocellular carcinoma (HCC) is notoriously difficult.
  • Seven patients (11%) were deemed nonoperable (five advanced disease by imaging, two comorbidities).
  • From 39 to 73% of patients had advanced local disease.
  • This frequently reflected advanced disease and HCV but may be associated with access to preventative and surveillance measures.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Referral and Consultation / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Hepatectomy / methods. Humans. Male. Middle Aged. Missouri / epidemiology. Postoperative Complications. Retrospective Studies. Urban Population

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1207-15; discussion 1215 [16332475.001]
  • [Cites] Arch Surg. 1999 Sep;134(9):984-92 [10487594.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20 [14762851.001]
  • [Cites] Liver Transpl. 2004 Nov;10(11):1422-7 [15497151.001]
  • [Cites] Semin Liver Dis. 1999;19(3):329-38 [10518312.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):734-44 [11922571.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):602-11 [12409666.001]
  • [Cites] J Gastrointest Surg. 2002 Jul-Aug;6(4):625-9 [12127131.001]
  • [Cites] J Surg Res. 1997 Jan;67(1):79-83 [9070186.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):100-4 [12511161.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2):235-43 [14762861.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):41-6 [12511147.001]
  • [Cites] Ann Surg. 1987 Jan;205(1):33-40 [3026259.001]
  • [Cites] J Am Coll Surg. 2003 Nov;197(5):730-8 [14585406.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1106-10 [10370675.001]
  • [Cites] Surgery. 1989 Oct;106(4):740-8; discussion 748-9 [2799650.001]
  • [Cites] Alcohol. 2002 May;27(1):69-72 [12062640.001]
  • [Cites] Transplantation. 1997 Jan 27;63(2):255-62 [9020327.001]
  • [Cites] J Am Coll Surg. 2005 Nov;201(5):656-62 [16256906.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Ann Surg. 2002 May;235(5):722-30; discussion 730-1 [11981219.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):887-97 [12788425.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):540-4; discussion 544-7 [16192814.001]
  • [Cites] Ann Surg. 1994 Mar;219(3):236-47 [8147605.001]
  • [Cites] Surgery. 2005 Apr;137(4):403-10 [15800485.001]
  • [Cites] J Bone Joint Surg Am. 2003 Jan;85-A(1):27-32 [12533568.001]
  • [Cites] World J Surg. 1986 Apr;10(2):311-7 [3010585.001]
  • [Cites] Surgery. 2003 Aug;134(2):142-5 [12947310.001]
  • [Cites] Dig Dis Sci. 2001 Jul;46(7):1393-8 [11478489.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2187-94 [15382089.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Oct;2(10):928-34 [15476157.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):210-5 [10024102.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Br J Surg. 1988 Apr;75(4):335-8 [2833979.001]
  • [Cites] Dig Dis Sci. 2000 Jul;45(7):1383-8 [10961718.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9 [14530722.001]
  • [Cites] N Engl J Med. 1994 Aug 18;331(7):444-9 [7880234.001]
  • (PMID = 17390191.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL: Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol; 2010 Jul;53(1):126-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
  • BACKGROUND & AIMS: Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC).
  • This phase II study evaluated the efficacy and safety of combining metronomic tegafur/uracil with sorafenib in patients with advanced HCC.
  • METHODS: Patients with histologically- or cytologically-proven HCC and Child-Pugh class A liver function were treated with sorafenib (400mg twice daily) and tegafur/uracil (125 mg/m(2) based on tegafur twice daily) continuously as first-line therapy for metastatic or locally advanced disease that could not be treated by loco-regional therapies.
  • CONCLUSIONS: Metronomic chemotherapy with tegafur/uracil can be safely combined with sorafenib and shows preliminary activity to improve the efficacy of sorafenib in advanced HCC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anorexia / chemically induced. Benzenesulfonates / administration & dosage. Diarrhea / chemically induced. Disease-Free Survival. Drug Eruptions / etiology. Fatigue / chemically induced. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Protein Kinase Inhibitors / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20416968.001).
  • [ISSN] 1600-0641
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 1548R74NSZ / Tegafur; 25X51I8RD4 / Niacinamide; 56HH86ZVCT / Uracil; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


88. Hotta N, Ayada M, Matsumoto E, Okumura A, Ishikawa T, Sato K, Oohashi T, Kakumu S: Usefulness of radiofrequency ablation with micro-convex probe for hepatocellular carcinoma. Hepatogastroenterology; 2009 Jul-Aug;56(93):1127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of radiofrequency ablation with micro-convex probe for hepatocellular carcinoma.
  • BACKGROUND/AIMS: It was aimed to assess whether a micro-convex probe is superior to the present conventional probe for ultrasonography from the points of safety and efficacy during percutaneous radiofrequency ablation therapy for hepatocellular carcinoma.
  • METHODOLOGY: Twenty-one patients with 23 hepatocellular carcinoma lesions who had one or 2 lesions, each 4 cm or less in diameter, and liver function of Child-Pugh class A or B were enrolled.
  • RESULTS: It was possible to perform safe and accurate percutaneous radiofrequency ablation procedure using micro-convex probes for the treatment of all hepatocellular carcinoma nodules.
  • It was also possible to treat hepatocellular carcinoma located in the right subphrenic region without artificial pleural effusion under intercostal ultrasonography guide.
  • The findings of advanced dynamic flow image on ultrasonography to assess the therapeutic efficacy indicated the consistency with those of dynamic CT which was done 3 to 5 days later radiofrequency ablation.
  • CONCLUSIONS: These results suggest that micro-convex probe with clustered tips is superior to conventional probe for ultrasonography from the points of safety and efficacy during radiofrequency ablation for hepatocellular carcinoma nodule located in the right subphrenic region and for larger sized nodule more than 3 cm.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / instrumentation. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Function Tests. Male. Middle Aged. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760955.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


89. Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, Gianella-Borradori A, Diéras V, Raymond E: Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer; 2010 Dec;46(18):3243-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
  • One partial response in a patient with hepatocellular carcinoma and sustained tumour stabilisations were observed.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug-Induced Liver Injury / etiology. Female. Humans. Male. Maximum Tolerated Dose. Metabolic Diseases / chemically induced. Middle Aged. Nausea / chemically induced. Vomiting / chemically induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20822897.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Purines; 0 / roscovitine
  •  go-up   go-down


90. Lee TK, Man K, Poon RT, Lo CM, Yuen AP, Ng IO, Ng KT, Leonard W, Fan ST: Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res; 2006 Oct 15;66(20):9948-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition.
  • Poor prognosis of hepatocellular carcinoma (HCC) is associated with a high potential of vascular invasion and metastasis.
  • We showed that activation of STAT5b, but not STAT5a, was found in HCC clinical samples and its expression was significantly associated with younger age (P = 0.037), advanced tumor stages (P = 0.003), venous infiltration (P = 0.016), microsatellite formation (P = 0.024), multiple tumor nodules (P = 0.02), and poor patient survival.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. STAT5 Transcription Factor / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cadherins / antagonists & inhibitors. Cadherins / metabolism. Cell Line, Tumor. Female. Hepatitis B / complications. Hepatitis B / genetics. Hepatitis B / metabolism. Hepatitis B virus / genetics. Hepatitis B virus / metabolism. Humans. Male. Middle Aged. Neoplasm Invasiveness. Trans-Activators. Transfection. Tumor Suppressor Proteins. Up-Regulation. Viral Regulatory and Accessory Proteins / genetics. Viral Regulatory and Accessory Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047057.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / STAT5 Transcription Factor; 0 / STAT5A protein, human; 0 / STAT5B protein, human; 0 / Trans-Activators; 0 / Tumor Suppressor Proteins; 0 / Viral Regulatory and Accessory Proteins; 0 / hepatitis B virus X protein
  •  go-up   go-down


91. Yamagami T, Kato T, Hirota T, Yoshimatsu R, Matsumoto T, White RI Jr, Nishimura T: Value of Micronester coils in port-catheter implantation for continuous hepatic arterial infusion chemotherapy with fixed catheter tip method. Eur Radiol; 2008 Jan;18(1):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cohort of this study was 143 consecutive patients with unresectable advanced liver cancer for whom a port-catheter system was percutaneously implanted.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Catheters, Indwelling. Embolization, Therapeutic / instrumentation. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiography, Digital Subtraction. Chi-Square Distribution. Contrast Media. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2002 Feb;12(2):443-9 [11870447.001]
  • [Cites] Radiology. 2004 Mar;230(3):792-802 [14739309.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1611-7 [12438064.001]
  • [Cites] Anticancer Res. 1994 Sep-Oct;14 (5B):2215-9 [7840526.001]
  • [Cites] Clin Radiol. 1999 Apr;54(4):221-7 [10210340.001]
  • [Cites] Radiology. 2000 Apr;215(1):294-9 [10751501.001]
  • [Cites] AJR Am J Roentgenol. 1977 Nov;129(5):799-803 [143878.001]
  • [Cites] Cancer. 1979 Aug;44(2):414-23 [157798.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):243-54 [10637236.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1332-9 [15788620.001]
  • [Cites] Angiology. 1990 Nov;41(11):936-41 [2244698.001]
  • [Cites] Cardiovasc Intervent Radiol. 1997 Mar-Apr;20(2):128-32 [9030504.001]
  • [Cites] J Vasc Interv Radiol. 2003 Jan;14(1):63-8 [12525587.001]
  • [Cites] Radiology. 1997 Feb;202(2):574-7 [9015093.001]
  • [Cites] Semin Oncol. 1983 Jun;10 (2):135-47 [6306833.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1112-8 [1296590.001]
  • [Cites] Lancet. 1994 Nov 5;344(8932):1255-60 [7526096.001]
  • [Cites] J Vasc Interv Radiol. 2001 Oct;12(10):1215-8 [11585889.001]
  • [Cites] Cardiovasc Intervent Radiol. 2003 Nov-Dec;26(6):554-6 [15061181.001]
  • (PMID = 17619883.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media
  •  go-up   go-down


92. Wang B, Tian HQ, Liang GW: [Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Mar;29(3):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer].
  • OBJECTIVE: To observe and compare the quality of life (QOL) and survival time in patients with advanced primary hepatic cancer (PHC) after they have been treated by the combination of ganji recipe and interventional therapy with Fructus Bruceae Oil Emulsion (FBE) or by the trans-hepatic arterial chemical embolization (TACE) adopting Seldinger's technique.
  • METHODS: Seventy-seven patients with advanced PHC were randomly assigned to two groups, 37 patients in the control group treated with TACE alone, and 40 in the treatment group with the combined therapy.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548447.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Plant Oils
  •  go-up   go-down


93. Cho SJ, Yoon JH, Hwang SS, Lee HS: Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol; 2007 Aug;22(8):1226-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients?
  • BACKGROUND AND AIM: The risk of hepatocellular carcinoma (HCC) is known to be age dependent; the influence of age on prognosis is, however, controversial.
  • CONCLUSIONS: Young HCC patients showed a poorer prognosis than older HCC patients because they have a more advanced tumor stage at diagnosis.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver / physiopathology. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498220.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


94. Pan HW, Chou HY, Liu SH, Peng SY, Liu CL, Hsu HC: Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma. Cell Cycle; 2006 Nov;5(22):2676-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma.
  • This study is to elucidate its function and clinicopathological significance in hepatocellular carcinoma (HCC) progression.
  • L2DTL overexpression is associated with enhanced metastatic potential of HCC, and contributes synergistically with p53 mutation, which leads to the loss of p53-governed checkpoints, toward advanced HCC with poor prognosis.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Carcinoma, Hepatocellular / metabolism. Cell Cycle. Centrosome / metabolism. Liver Neoplasms / metabolism. Nuclear Proteins / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cadherins / metabolism. Down-Regulation. HeLa Cells. Humans. Middle Aged. RNA, Messenger / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Ubiquitin-Protein Ligases


95. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology; 2005 Jul;42(1):121-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the lamivudine-treated patients, 4 died, 1 underwent a transplantation, and another 8 developed major events, all having advanced fibrosis at baseline and all but 1 having experienced breakthroughs or no response.
  • In such patients with advanced fibrosis, close follow-up for lamivudine resistance and prompt onset of additional antiviral therapy is required or the ab initio use of agent(s) with low resistance rates should be considered.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Hepatocellular / etiology. Female. Hepatitis B e Antigens / immunology. Humans. Interferon-alpha / therapeutic use. Liver Failure / etiology. Liver Neoplasms / etiology. Male. Middle Aged. Nucleosides / agonists. Nucleotides / agonists. Organophosphonates / therapeutic use. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis E.
  • Hazardous Substances Data Bank. Adefovir .
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962291.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis B e Antigens; 0 / Interferon-alpha; 0 / Nucleosides; 0 / Nucleotides; 0 / Organophosphonates; 2T8Q726O95 / Lamivudine; 6GQP90I798 / adefovir; JAC85A2161 / Adenine
  •  go-up   go-down


96. Ahn SH, Yuen L, Han KH, Littlejohn M, Chang HY, Damerow H, Ayres A, Heo J, Locarnini S, Revill PA: Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol; 2010 Jul;82(7):1126-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The complete HBV genome sequences from 53 Korean patients with chronic hepatitis B, advanced cirrhosis, or hepatocellular carcinoma (HCC) were analyzed to identify (i) subgenotype distribution and genetic diversity and (ii) signature mutations associated with liver disease progression.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Hepatitis B virus / genetics. Hepatitis B, Chronic / pathology. Hepatitis B, Chronic / virology. Liver Cirrhosis / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Aged. Amino Acid Substitution. Disease Progression. Female. Genome, Viral. Humans. Male. Middle Aged. Molecular Sequence Data. Phylogeny. Republic of Korea. Young Adult

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20513074.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GQ475305/ GQ475306/ GQ475307/ GQ475308/ GQ475309/ GQ475310/ GQ475311/ GQ475312/ GQ475313/ GQ475314/ GQ475315/ GQ475316/ GQ475317/ GQ475318/ GQ475319/ GQ475320/ GQ475321/ GQ475322/ GQ475323/ GQ475324/ GQ475325/ GQ475326/ GQ475327/ GQ475328/ GQ475329/ GQ475330/ GQ475331/ GQ475332/ GQ475333/ GQ475334/ GQ475335/ GQ475336/ GQ475337/ GQ475338/ GQ475339/ GQ475340/ GQ475341/ GQ475342/ GQ475343/ GQ475344/ GQ475345/ GQ475346/ GQ475347/ GQ475348/ GQ475349/ GQ475350/ GQ475351/ GQ475352/ GQ475353/ GQ475354/ GQ475355/ GQ475356/ GQ475357
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Wu L, Peng CW, Hou JX, Zhang YH, Chen C, Chen LD, Li Y: Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation. J Exp Clin Cancer Res; 2010;29:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation.
  • BACKGROUND: To better search for potential markers for hepatocellular carcinoma (HCC) invasion and metastasis, proteomic approach was applied to identify potential metastasis biomarkers associated with HCC.
  • IHC study on human HCC specimens revealed that more patients in the higher coronin-1C group had overt larger tumor and more advanced stage.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Microfilament Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Cell Line, Tumor. Female. Humans. Lung Neoplasms / secondary. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Proteomics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chim Acta. 2001 Nov;313(1-2):15-9 [11694234.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):814-21 [10555751.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):824-34 [12209727.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48858-67 [12377779.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jan;129(1):43-51 [12618900.001]
  • [Cites] Horm Res. 2003;60(4):174-80 [14530605.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7553-62 [14633666.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Mol Cell Proteomics. 2004 Jan;3(1):73-81 [14593079.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Apr;130(4):187-96 [14685850.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Aug;130(8):460-8 [15146329.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5434-41 [15289352.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):497-513 [15205947.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7329-35 [15492253.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] Hepatology. 1984 Sep-Oct;4(5):889-92 [6207091.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6844-9 [3180092.001]
  • [Cites] Cancer Res. 1991 Aug 1;51(15):4080-3 [1649698.001]
  • [Cites] EMBO J. 1991 Dec;10(13):4097-104 [1661669.001]
  • [Cites] Hepatology. 1993 Oct;18(4):990-7 [8406374.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5179-84 [9371521.001]
  • [Cites] J Hepatol. 2004 Nov;41(5):864-80 [15519663.001]
  • [Cites] Transplantation. 1963 Apr;1:174-80 [14010646.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Bioessays. 2005 Jun;27(6):625-32 [15892111.001]
  • [Cites] J Hepatol. 2005 Dec;43(6):1007-12 [16137783.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Aug;132(8):515-20 [16788845.001]
  • [Cites] Trends Cell Biol. 2006 Aug;16(8):421-6 [16806932.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):3-4 [18043872.001]
  • [Cites] J Pathol. 2008 Mar;214(4):415-24 [18189330.001]
  • [Cites] J Hepatol. 2008;48 Suppl 1:S20-37 [18304676.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Dec;26(4):527-33 [18365549.001]
  • [Cites] J Cell Biol. 2008 Jun 16;181(6):879-84 [18541702.001]
  • [Cites] Oncology. 2008;75 Suppl 1:1-12 [19092266.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Aug;135(8):969-81 [19399516.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:122 [19715608.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:126 [19740432.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:144 [19930704.001]
  • [Cites] World J Gastroenterol. 2001 Oct;7(5):630-6 [11819844.001]
  • (PMID = 20181269.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Microfilament Proteins; 145420-64-0 / coronin proteins
  • [Other-IDs] NLM/ PMC2845108
  •  go-up   go-down


98. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW, Jaeger D, von Kalle C, Schemmer P: Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer; 2008;8:349
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
  • BACKGROUND: Disease progression of hepatocellular cancer (HCC) in patients eligible for liver transplantation (LTx) occurs in up to 50% of patients, resulting in withdrawal from the LTx waiting list.
  • The oral multikinase inhibitor sorafenib significantly increases overall survival and time-to-progression in patients with advanced hepatocellular cancer.
  • A total of 208 patients with histologically confirmed hepatocellular carcinoma or HCC diagnosed according to EASL criteria will be enrolled.
  • DISCUSSION: As TACE is the most widely used primary treatment of HCC before LTx and sorafenib is the only proven effective systemic treatment for advanced HCC there is a strong rational to combine both treatment modalities.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Pyridines / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Double-Blind Method. Female. Humans. Liver Transplantation. Male. Niacinamide / analogs & derivatives. Phenylurea Compounds. Research Design

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2004 Nov;40(16):2439-44 [15519517.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):795-804 [15760404.001]
  • [Cites] Liver Transpl. 2005 Jul;11(7):767-75 [15973710.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S105-8 [16286885.001]
  • [Cites] Liver Transpl. 2005 Dec;11(12):1505-14 [16315294.001]
  • [Cites] Liver Transpl. 2006 Apr;12(4):665-73 [16482577.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Hepatology. 2003 Feb;37(2):429-42 [12540794.001]
  • [Cites] Liver Transpl. 2003 Jun;9(6):557-63 [12783395.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Liver Transpl. 2004 Mar;10(3):449-55 [15004776.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] N Engl J Med. 1995 May 11;332(19):1256-61 [7708069.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Ann Surg. 1997 Dec;226(6):688-701; discussion 701-3 [9409568.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1578-83 [9620330.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):788-94 [15760403.001]
  • (PMID = 19036146.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN24081794
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC2630329
  •  go-up   go-down


99. Nagino M, Kamiya J, Arai T, Nishio H, Ebata T, Nimura Y: "Anatomic" right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma. Ann Surg; 2006 Jan;243(1):28-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The techniques of right hepatic trisectionectomy are now standardized in patients with hepatocellular or metastatic carcinoma, but not in those with hilar cholangiocarcinoma.
  • CONCLUSIONS: Anatomic right hepatic trisectionectomy with caudate lobectomy can produce a longer proximal resection margin and can offer a better chance of long-term survival in some selected patients with advanced hilar cholangiocarcinoma.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2003 Nov;238(5):720-7 [14578735.001]
  • [Cites] Surgery. 2000 Feb;127(2):155-60 [10686980.001]
  • [Cites] J Hepatol. 2003 Oct;39(4):475-9 [12971954.001]
  • [Cites] Surg Gynecol Obstet. 1975 Sep;141(3):429-37 [1162576.001]
  • [Cites] Surg Gynecol Obstet. 1980 Feb;150(2):208-14 [7352313.001]
  • [Cites] Surg Gynecol Obstet. 1983 Mar;156(3):302-4 [6828972.001]
  • [Cites] Radiology. 1985 Jan;154(1):31-6 [3964948.001]
  • [Cites] Surg Gynecol Obstet. 1986 Feb;162(2):189-90 [3945901.001]
  • [Cites] Surg Gynecol Obstet. 1989 May;168(5):457-8 [2711300.001]
  • [Cites] Surgery. 1990 Jun;107(6):597-604 [2162082.001]
  • [Cites] World J Surg. 1990 Jul-Aug;14(4):535-43; discussion 544 [2166381.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):31-8 [1309988.001]
  • [Cites] Hepatogastroenterology. 1992 Aug;39(4):296-300 [1427569.001]
  • [Cites] World J Surg. 1993 Jan-Feb;17(1):85-92; discussion 92-3 [8447147.001]
  • [Cites] Endoscopy. 1993 Jan;25(1):76-80 [8384103.001]
  • [Cites] Arch Surg. 1993 Aug;128(8):871-7; discussion 877-9 [8393652.001]
  • [Cites] Surgery. 1994 Apr;115(4):445-51 [8165536.001]
  • [Cites] Hepatology. 1995 Feb;21(2):434-9 [7843717.001]
  • [Cites] Surgery. 1995 Jun;117(6):677-81 [7778031.001]
  • [Cites] Arch Surg. 1995 Jul;130(7):759-63 [7611866.001]
  • [Cites] Hepatogastroenterology. 1995 Jul-Aug;42(4):323-31 [8586362.001]
  • [Cites] Surgery. 1996 May;119(5):592-5 [8619217.001]
  • [Cites] Radiology. 1996 Aug;200(2):559-63 [8685357.001]
  • [Cites] Hepatogastroenterology. 1997 Jul-Aug;44(16):998-1001 [9261589.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):405-11 [9527064.001]
  • [Cites] Arch Mal Appar Dig Mal Nutr. 1952 Jun;41(6):662-7 [12986992.001]
  • [Cites] Langenbecks Arch Surg. 2002 Jul;387(3-4):188-9 [12172866.001]
  • (PMID = 16371733.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1449975
  •  go-up   go-down


100. Obed A, Tsui TY, Schnitzbauer AA, Obed M, Schlitt HJ, Becker H, Lorf T: Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified? Langenbecks Arch Surg; 2008 Mar;393(2):141-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified?
  • BACKGROUND: Liver transplantation is considered as one of therapeutic approaches to hepatocellular carcinoma (HCC).
  • There were no significant differences in 1- and 5-year survivals of patients with early tumour stage received LTx or primary tumour resection, whereas patients in advanced tumour stage based on pathological findings of explanted liver significantly benefited from LTx as compared to primary resection.
  • CONCLUSIONS: LTx can be a curative approach for patients with advanced HCC without extrahepatic metastasis.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Dec;30(6):1434-40 [10573522.001]
  • [Cites] Liver Transpl. 2006 Aug;12(8):1260-7 [16826556.001]
  • [Cites] Hepatology. 2001 May;33(5):1080-6 [11343235.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Liver Transpl. 2001 Oct;7(10):877-83 [11679986.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5):474-86 [11685740.001]
  • [Cites] Ann Surg. 2002 May;235(5):722-30; discussion 730-1 [11981219.001]
  • [Cites] Hepatology. 2002 May;35(5):1164-71 [11981766.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9 [14530722.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45 [14762838.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):796-802 [15305412.001]
  • [Cites] Ann Surg. 1993 Aug;218(2):145-51 [8393649.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:9-16 [9210883.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1572-7 [9620329.001]
  • [Cites] Transpl Int. 1998;11 Suppl 1:S189-92 [9664976.001]
  • [Cites] J Hepatol. 1998 Jul;29(1):129-34 [9696501.001]
  • [Cites] J Hepatol. 1998 Dec;29(6):953-9 [9875642.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):324-31 [10458250.001]
  • [Cites] Am J Transplant. 2005 Apr;5(4 Pt 1):795-804 [15760404.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):331-47 [15837037.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S113-9 [16286887.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):212-7 [16613896.001]
  • [Cites] Transplant Proc. 2006 May;38(4):1111-3 [16757280.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1224-9 [11093728.001]
  • (PMID = 18043937.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3085731
  •  go-up   go-down






Advertisement